



## **CURRICULUM VITAE**

**Michael A. Davies, M.D., Ph.D.**

### **PRESENT TITLE AND AFFILIATION**

#### **Primary Appointment**

Chair, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Co-Leader Melanoma Moon Shot Program, Moon Shots Program, The University of Texas MD Anderson Cancer Center, Houston, TX

Director of Research Activities, Hematology/Oncology Fellowship Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

#### **Dual/Joint/Adjunct Appointment**

Professor, Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

### **CITIZENSHIP**

United States

### **OFFICE ADDRESS**

The University of Texas MD Anderson Cancer Center  
1515 Holcombe Blvd.  
Unit Number: 430  
Houston, TX 77030  
Room Number: FC11.3028  
Phone: (713) 792-2921  
Fax: (713) 745-1046

The University of Texas MD Anderson Cancer Center  
2130 W. Holcombe Blvd  
Unit Number: 904  
Houston, TX 77030  
Room Number: LSP12.3020  
Phone: 713-563-5270  
Fax: 713-563-3424  
Email: MDavies@mdanderson.org

### **EDUCATION**

#### **Degree-Granting Education**

The University of Texas at Austin, Austin, TX, BA, 1993, Liberal Arts

The University of Texas Health Science Center, Houston, TX, MD, PhD, 2001, Molecular Biology

#### **Postgraduate Training**

Clinical Residency, Internal Medicine, Massachusetts General Hospital, Boston, MA, 7/2001-6/2004

Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2004-6/2007

## **CREDENTIALS**

### **Board Certification**

American Board of Internal Medicine, 8/2004-12/2014

Medical Oncology, 11/2007-5/2028

### **Licensures**

#### **Active**

Texas Medical License, TX, L9165, 2004-8/2019

#### **Inactive**

Massachusetts Medical License, MA, N/A, 2002-2004

## **EXPERIENCE/SERVICE**

### **Academic Appointments**

Undergraduate Research Assistant, Pharmacy, The University of Texas at Austin, Austin, TX, 1/1991-1/1994

Undergraduate Research Assistant, Allergan Pharmaceuticals, Irvine, CA, 5/1993-7/1993

Teaching Assistant, Neuro-anatomy, University of Texas Medical School, Houston, TX, 1996

Graduate Research Assistant, Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/1997-12/1997

Graduate Research Assistant, Neuro-oncology and Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1998-6/2001

Intern, Internal Medicine, Massachusetts General Hospital, Boston, MA, 2001-2002

Resident, Internal Medicine, Massachusetts General Hospital, Boston, MA, 2002-2004

Fellow, Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2004-6/2007

Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2007-8/2014

Professor, Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2008-present

Assistant Professor, Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2008-8/2014

Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2014-9/2019

Deputy Chair, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015-2019

Professor, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2015-present

Chair, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2019-present

Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2019-present

### **Administrative Appointments/Responsibilities**

Course Director, Division of Cancer Medicine, Core Curriculum Course, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2005-8/2006

MD/PhD Program Admissions Committee Member, The University of Texas Health Science Center, Houston, TX, 2008-present

Director of Melanoma and Skin Cancer SPORE Series, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2011-present

Co-Leader Melanoma Moon Shot Program, Moon Shots Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2012-present

Member, Executive Committee, Hematology/Oncology Fellowship Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013-present

Faculty Mentor, Medical Oncology Fellowship Program associated with T32 CA009666 - Research Training in Academic Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2013-present

Director of Research Activities, Hematology/Oncology Fellowship Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2013-present

Co-Chair, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2015-9/2019

#### **Other Appointments/Responsibilities**

Graduate Faculty Member, Graduate School of Biomedical Sciences, Houston, TX, 2008-present

Member, MRF Breakthrough consortium (MRFBC) Translational Subcommittee, Houston, 2010-present

Member, International Melanoma Working Group, Naples, Italy, 2010-present

Member, MRF Breakthrough Consortium (MRFBC) Signal Transduction Subcommittee, Houston, 2011-present

Member, The TCGA Melanoma Analysis Working Group, Houston, TX, 9/2012-present

Member, Executive Committee, Society for Melanoma Research, Burnt Hills, NY, 11/2013-present

Member Organizing Committee, 2016 SMR Congress, Boston, MA, 11/2016

Melanoma Senior Editor, Clinical Cancer Research, Chicago, IL, 1/2017-6/2019

#### **Endowed Positions**

N/A

#### **Consultantships**

Baylor College of Medicine T32 Program, Houston, External Advisory Board, 6/2019-present

Vanderbilt University Medical Center, Nashville, External Advisory Board Member, 6/2019-present

University of Pennsylvania SPORE, Pennsylvania, External Advisory Board Member, 7/2019-present

#### **Military or Other Governmental Service**

N/A

#### **Institutional Committee Activities**

South Campus Transportation Committee, Member, 7/2009-present

MDACC IRG Grant Review Study Section/Committee, Member, 8/2009-present

Pharmacy & Therapeutics Committee, Member, 9/2009-present

Molecular Testing Task Force, Member, 8/2010-present

MDACC Clinical Research Committee, Member, 9/2011-9/2015

Molecular Tumor Board, Member, 8/2012-present

Advanced Scholar Program Executive Committee, Member, 2013-present  
MDACC Clinical Research Committee, Member, 9/2013-9/2019  
MD Anderson Clinical Research Committee, Co-Chair, 9/2015-9/2019

## **HONORS AND AWARDS**

Phi Beta Kappa, Undergraduate Honor Society, Phi Beta Kappa, 1993  
Cancer Answers/Sylvan Rodriguez Scholarship, Graduate School of Biomedical Sciences, 1999  
President's Research Scholarship, Graduate School of Biomedical Sciences, 1999  
Alpha Omega Alpha, Medical Honor Society, 2000  
Amgen Award in Basic Science Research, MD Anderson Cancer Center, 2000  
Young Investigator Award, American Society of Clinical Oncology, 2005  
Carol Codgell Courtney Fellowship, MD Anderson Cancer Center, 2006  
Outstanding Achievement in Basic Science Research, Medical Oncology Fellowship Program, MD Anderson Cancer Center, 2007  
Team Science Award, MD Anderson Cancer Center, 2009  
ASCO Career Development Award, American Society of Clinical Oncology, 2010  
Goodfellow Scholar, MD Anderson Cancer Center, 2010-2011  
Wilson S. Stone Memorial Award, MD Anderson Cancer Center, 2010  
Gerald P. Bodey Award for Excellence in Education, MDACC Division of Cancer Medicine, 2015  
Leadership in Education, Division of Cancer Medicine, MD Anderson Cancer Center, MD Anderson Cancer Center, 2015  
Member, American Society for Clinical Investigation, 2016  
2019 Mentor of the Year Award, MD Anderson Division of Cancer Medicine Hematology/Oncology Fellowship Program, 2019

## **RESEARCH**

### **Grants and Contracts**

#### **Funded**

Co-Principal Investigator, 8%, The Role of the PI3K Pathway in Immune Resistance, 1R01CA187076-02, NIH/NCI, 8/13/2014-7/31/2019, \$1,660,000

Principal Investigator, Identifying rational therapeutic approaches for "Wild Type" Melanoma, 01, Melanoma Research Foundation, 10/1/2014-9/30/2019, \$500,000

Co-Principal Investigator, 10%, Research Training in Academic Medical Oncology, 2T32CA009666-21, NIH/NCI, 5/1/2015-4/30/2020, \$437,262

Principal Investigator, 0.12 months, Phase II Open Label Two Arm Study of the MEK Inhibitor Trametinib to investigate the Safety and Anti Cancer Activity in subjects with Melanoma with BRAF non-V600 Mutations, 13835, National Comprehensive Cancer Network, 6/8/2015-12/31/2019, \$187,936

Principal Investigator, 1.2 months, Exploiting molecular and metabolic dependencies to optimize personalized therapeutic approaches for melanomas, RP160183, Cancer Prevention & Research Institute of Texas (CPRIT), 3/1/2016-8/31/2019, \$900,000

Co-Investigator, 0.12 months, Promoting a Bim-driven apoptosis through MAPK inhibition" A therapeutic strategy in advanced melanoma, 1R01CA193970-01A1, NIH/NCI, PI - Ryan Sullivan, 4/1/2016-3/31/2021, \$80,000

Collaborator, 5%, Targeting the Glycolysis Pathway to Overcome Resistance to Cancer Immunotherapy, RP170401, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Patrick Hwu, 12/1/2016-11/30/2019, \$900,000

Co-Investigator, 0.12 months, PKC as Node to Overcome Intrinsic MEK Inhibitor Resistance in Melanoma, 508743, Melanoma Research Alliance, PI - Lawrence Kwong, 5/15/2017-5/14/2020, \$225,000

Co-Principal Investigator, 1.8 months, Rational approaches to melanoma therapy, 1U54CA224070-01, NIH/NCI, 9/1/2017-8/31/2022, \$7,182,435

Principal Investigator, 1.2 months, Understanding and Improving Outcomes in Refractory Melanoma, 01, Adelson Medical Research Foundation, 10/1/2017-9/30/2019, \$711,889

Co-Principal Investigator, 0.96 months, Integration of Clinical, Molecular, and Immune Features to Improve Risk Stratification and Outcomes in Melanoma Patients with Sentinel Lymph Node Metastasis, CA170374, DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP), 9/1/2018-8/31/2023, \$1,594,420

Co-Principal Investigator, 1.2 months, UT M.D. Anderson SPORE in Melanoma – Project 1: Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of PTEN, NIH/NCI, 7/8/2019-8/31/2023, \$2,297,865

Core Leader, 0.6 months, UT M.D. Anderson SPORE in Melanoma – Core B: Melanoma Clinical Database, Tissue Resource, and Translational Pathology Core, NIH/NCI, 7/8/2019-present, \$1,200,000

Co-Director, 1.2 months, UT M.D. Anderson SPORE in Melanoma-Administrative Core, NIH/NCI, 7/16/2019-5/31/2024, \$1,316,420

#### **Pending**

Principal Investigator, 5%, Functional Proteomics RPPA Platform at MDAnderson, Adelson, 9/1/2019-8/31/2022, \$429,659

Principal Investigator, 5%, Improving outcomes in refractory advanced melanoma, Adelson, 9/1/2019-8/31/2022, \$1,063,433

Principal Investigator, Molecular predictors and vulnerabilities of melanoma brain metastasis, American Cancer Society/Melanoma Research Alliance, 1/1/2020-12/31/2023, \$999,999

Principal Investigator, Targeting oxidative phosphorylation to reduce the incidence and therapeutic resistance of melanoma brain metastasis, NIH/NCI, 4/1/2020-3/31/2025, \$3,326,022

Co-Principal Investigator, Therapeutic Potential of Targeting GPER in Cancer, NIH/NCI, \$500,000

#### **Other**

N/A

#### **Completed**

Principal Investigator, 0.12 months, A Phase 1/1b study for the evaluation of SAR260301, administered orally in monotherapy in patients with advanced solid tumors or lymphomas, and in combination with vemurafenib in patients with unresectable/metastatic BRAF mutated melanoma, SAR260301, Sanofi S.A., 11/26/2008-11/25/2017, \$1,138,947

Core Co-Leader, 5%, UT MD Anderson Cancer Center SPORE in Melanoma (PC-B), 5 P50 CA093459-10, NIH/NCI, PI - Patrick Hwu, 9/15/2010-8/31/2015 (\$187,006/year)

Collaborator, 2%, Using the MHC class 1 cytoplasmic tail to control tumor Ag presentation by DCs, NIH/NCI, PI - Gregory Lizee, 12/1/2010-11/30/2015, \$1,250,000 (\$250,000/year)

Principal Investigator, 17%, The Role of the PI3K-AKT Pathway in Melanoma Brain Metastases, 5R01CA154710-04, NIH/NCI, 2/9/2011-1/31/2016, \$1,609,744 (\$318,015/year)

Co-Principal Investigator, 0.36 months, Team Science: Clinicopathologic and Molecular Staging & Prognosis in Early-Stage Melanoma, Melanoma Research Alliance, PI - Jeffrey Gershenwald, 8/1/2011-7/31/2015, \$1,000,000 (\$333,333/year)

Principal Investigator, 5%, Clinical and molecular characterization of combined BRAF and MEK inhibitor treatment in patients with metastatic melanoma resistant to BRAF inhibitor alone., RP120505, Cancer Prevention & Research Institute of Texas (CPRIT), 12/1/2011-5/30/2015, \$1,016,799 (\$284,031/year)

Principal Investigator, 1%, Patterns and Outcomes of Treatment Sequencing in Metastatic Melanoma, C4-159443, Genentech, 10/10/2012-10/11/2015, \$65,249 (\$21,750/year)

Principal Investigator, 1%, Optimizing Patient Selection and Overcoming Resistance for Therapies for Advanced Melanoma, 01, Adelson Medical Research Foundation, 2/27/2013-9/30/2015, \$571,455 (\$190,485/year)

Principal Investigator, 1%, Evaluation of the Immune Response in Tumor biopsies from Melanoma Patients Treated with Dabrafenib (GXK2118436) +/- Trametinib (GSK1120212) in Combination with Ipilimumab, GlaxoSmithKline, 4/20/2013-4/19/2016, \$184,000 (\$61,333/year)

Principal Investigator, 1.2 months, Targeting BRAF-mutant melanoma brain metastases, 01, Melanoma Research Alliance, 5/1/2013-12/31/2018, \$900,000

Principal Investigator, 0.12 months, An Open-Label, Multicenter, Corollary Study of Pre-Operative Therapy with Dabrafenib, BRV116521, GSK Biologicals, 1/30/2014-1/30/2019, \$281,055

Principal Investigator, 1%, A High-Throughput Model for Human Melanoma, 3-R01-CA121118-06A1, University of Utah, 4/1/2014-5/31/2015, \$6,888 (\$6,888/year)

Collaborator, 0.12 months, A High-Throughput Model for Human Melanoma, 2R01CA121118-06A1, NIH/NCI, PI - Sheri Holmen, 4/1/2014-5/31/2016, \$6,888

Collaborator, A High-Throughput Model for Human Melanoma, 2R01CA121118-06A1, NIH/NCI, PI - Holmen, 4/1/2014-5/31/2018

Principal Investigator, 0.12 months, BRF117277, A Phase II, Open-Label, Multicenter Study of Dabrafenib plus Trametinib, BRF117277, GlaxoSmithKline, 8/28/2014-1/3/2018, \$399,725

Principal Investigator, 0.12 months, In Vitro and In Vivo Effects of SAR260301 on the Anti-Tumor Immune Response, 38876, Sanofi S.A., 9/5/2014-9/4/2017, \$109,808

Principal Investigator, 10%, Rational New Therapeutic Approaches to Overcome Resistance in Melanoma, Adelson Medical Research Foundation, 10/1/2014-9/30/2015, \$188,264 (\$188,264/year)

Principal Investigator, Molecular basis of therapeutic resistance and brain metastasis in melanoma, SINF, 5/18/2016-5/17/2018, \$100,000

Co-Investigator, 0.12 months, Understanding the immune-biology of checkpoint inhibitors to develop new strategies for therapy, CA 150619P2, DOD Translational Team Science Award, PI - Herlyn, 7/1/2016-6/30/2019, \$75,000

#### **Not Funded**

Core Co-Leader, 5%, The University of Texas MD Anderson Cancer Center SPORE in Melanoma, 2P50CA093459-11, NIH/NCI, PI - Hwu P, 12/1/2001-8/31/2020 (\$180,220/year)

Principal Investigator, 3 months, The Development of Rational Approaches for Brain Metastases, 1DP2OD007187-01, NIH/NCI, 9/30/2010-7/31/2015, \$1,500,000 (\$300,000/year)

Collaborator, 2%, BRAF-mediated senescence, apoptosis, and synthetic lethality in lung cancer, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Faye Johnson, 12/1/2011-11/30/2014, \$349,325 (\$1,047,975/year)

Co-Investigator, 3%, Signaling Pathways and Therapeutic Targets in 'wild-type' Melanoma, Melanoma Research Alliance, PI - Katherine Nathanson, 5/1/2012-4/30/2015, \$1,888,856 (\$62,952/year)

Collaborator, 1.2 months, Strategies to improve immunotherapy for melanoma brain metastases, NIH/NCI, 7/1/2013-6/30/2021, \$450,000

Principal Investigator, 1.2 months, Clinical significance and targeting of oxidative phosphorylation in melanoma, GRANT11497965, NIH/NCI, 7/1/2014-6/30/2019 (\$250,000/year)

Co-Investigator, 5%, Bayesian approaches for heterogeneous molecular networks in cancer, NIH/NCI, PI - Dr. Francesco Stingo, 7/1/2015-6/30/2020, \$1,250,000 (\$250,000/year)

Principal Investigator, 1.2 months, Characterizing unusual responders to optimize the use of targeted therapies for BRAF-mutant metastatic melanoma, CA150628, DoD Translational Team Science Award, 3/1/2016-2/28/2019, \$720,003

Collaborator, 1.2 months, Targeting the PI3K/Akt pathway to improve immunotherapy for melanoma brain metastases, CA12345, DoD Translational Team Science Award, PI - Kluger, 3/1/2016-2/28/2019, \$390,000

Co-Investigator, 0.6 months, Understanding the Immune-Biology of Checkpoint Inhibitors to Develop New Strategies for Therapy, Team Science Grant, Melanoma Research Alliance, PI - Herlyn, 5/1/2016-4/30/2019, \$225,000

Co-Investigator, 1.2 months, Strategies to improve immunotherapy for melanoma brain metastases, R01, NIH/NCI, PI - Kluger, 7/1/2016-6/30/2021, \$450,000

Co-Project Leader, 1.8 months, Administrative Supplement to Study Mechanisms of Cancer Sensitivity and Resistance to Therapy Utilizing Samples and Information from Human Clinical Trials, P30CA016672, NIH/NCI, PI - DePinho, Ronald, 9/1/2016-8/30/2017, \$750,000 (\$468,750/year)

Co-Principal Investigator, 1.8 months, Combining targeted therapy and immunotherapy in advanced melanoma, 1R01CA215122-01, NIH/NCI, PI - Davies/Wargo, 4/1/2017-3/31/2022, \$1,250,000

Principal Investigator, 2.4 months, Immune and metabolic parthenogenesis of melanoma brain metastasis, 2R01CA154710-10, NIH/NCI, 9/1/2017-8/31/2022, \$2,000,000

Co-Director, 0.6 months, Core 2: Melanoma Clinical Database, Tissue Resource and Translational Pathology Core (MelCore), P50CA221703-01, NIH/NCI, PI - Patrick Hwu, 12/1/2017-11/30/2022, \$11,500,000 (\$150,840/year)

Co-Leader, 1.2 months, Project 1, Targeting the PI3K Pathway to Overcome Resistance to Immunotherapy in Melanomas with Loss of Pten, P50CA221703-01, NIH/NCI, PI - Patrick Hwu, 12/1/2017-11/30/2022, \$11,500,000 (\$236,187/year)

Principal Investigator, 2.4 months, Integrative molecular and immune analysis of a Phase I/II trial of GSK2636771 in combination with pembrolizumab in metastatic melanoma patients with PTEN loss, RP180467, Cancer Prevention & Research Institute of Texas (CPRIT), 3/1/2018-2/28/2021, \$383,602

Collaborator, 1%, Biomarker-directed proof-of-concept phase I trial of the first-in-class OXPPOS inhibitor IACS-010759 in patients with advanced solid tumors, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Timothy Yap, 3/1/2018-2/28/2022, \$2,396,525

## **Protocols**

### **Funded**

Collaborator, Randomized Phase II Neoadjuvant Study of Temozolomide alone or with Pegylated Interferon-alpha 2b in Patients with Resectable AJCC Stage IIIB/IIIC or Stage IV (M1a) Metastatic Melanoma, 2005-0143, PI - Wen-Jen Hwu, 2005-2010

Co-Principal Investigator, A Phase 1/2 Study of the Combination of BAY 43-9006 (sorafenib) and CCI-779 (temsirolimus) in Patients with Metastatic Melanoma (targeted Molecular Therapeutics for Melanoma:CCI-779 and Bevacizumab), N01-CM-17003 03 (25XS068), 2005-0215, 2006-2010, \$159,436 (\$77,122/year), NIH/NCI/CTEP

Collaborator, Blood and Tumor Sample Collection from Patients with Uveal Melanoma, LAB07-0262, PI - Bitá Esmaeli, 2007-present, Sponsored Projects - Head & Neck

Principal Investigator, A Phase 1/1b study for the evaluation of SAR260301, administered orally in monotherapy in patients with advanced solid tumors or lymphomas, and in combination with vemurafenib in patients with unresectable/metastatic BRAF mutated melanoma, 2012-0470, 2008-2017, \$1,138,947 (\$126,550/year), Sanofi S.A.

Collaborator, A Phase 2 Study of Intralesional PV-10 in the Treatment of Metastatic Melanoma MDACC, 2008-0093, 2008-present

Principal Investigator, Analysis of protein signaling networks and gene expression in resected melanoma brain metastases, LAB05-0616, 2008-present

Principal Investigator, Patients treated with high-dose bolus interleukin-2 therapy at The University of Texas M.D. Anderson Cancer Center, DR07-0765, 2008-present

Principal Investigator, Identifying Therapeutic Targets for Melanoma Brain Metastases, LAB05-0616, 2010-2012

Principal Investigator, Comparative Analysis of PTEN Testing Methodologies and Melanoma Clinical Outcomes, LAB10-0732, 2010-present

Principal Investigator, The Molecular Biology of Melanoma Brain Metastases, LAB10-0519, 2010-present

Principal Investigator, Clinical and molecular characterization of combined BRAF and MEK inhibitor treatment in patients with metastatic melanoma resistant to BRAF inhibitor alone., 2011-0579, 2011-2014 (\$1,016,800/year), Cancer Prevention & Research Institute of Texas (CPRIT)

Principal Investigator, BRF113929: A Phase II Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naive and Previously Treated Subjects with BRAF Mutation-Positive Metastatic Melanoma to the Brain., 2010-0841, 2011-present, \$830,012 (\$105,602/year), Glaxo Smith Kline

Principal Investigator, Comparative Molecular Analysis of OCT-embedded and FFPE Tissue Samples, PA11-0859, 2011-present, Myriad

Principal Investigator, Effects of PTEN Inhibition in Melanoma, DR11-0044, 2011-present

Principal Investigator, Mechanisms of Resistance to MAPK Pathway Inhibitors in Melanoma, PA12-1163, 2013-2014

Collaborator, Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer- Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II), PA12-1161, PI - Tsimberidou AM, 2014-2015, \$471,168,624 (\$3,772,959/year), Foundation Medicine Inc

Principal Investigator, BRF117277, A Phase II, Open-Label, Multicenter Study of Dabrafenib plus Trametinib, 2013-1020, 2014-2016, \$399,725 (\$199,863/year), GlaxoSmith Kline

Principal Investigator, A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, trametinib, Combined with the CDK4/6 Inhibitor, palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects with Solid Tumors., 2013-0793, 2014-2019, \$1,374,330 (\$274,866/year), Glaxo Smith Kline

Principal Investigator, An Open-Label, Multicenter, Corollary Study of Pre-Operative Therapy with Single Agent GSK2118436 in Subjects with BRAF Mutation-Positive Metastatic Melanoma to the Brain, 2012-0208, 2014-2019, \$281,055 (\$56,211/year), Glaxo Smith Kline



Principal Investigator, Array trial for brain mets, 2019-0031, 2019-present, Array Biopharma

**Unfunded**

N/A

**Patents and Technology Licenses**

**Patents**

N/A

**Technology Licenses**

N/A

**Grant Reviewer/Service on Study Sections**

Genesis Oncology Trust, Private, Reviewer, 2009

Harry J. Lloyd Charitable Trust, Private, Reviewer, 2010-2011

Wellcome Trust Limited, Private, Reviewer, 2011

Melanoma Research Foundation, Private, Reviewer, 2011-present

European Research Council, Private, Reviewer, 2012

Florida Department of Health, Public, Reviewer, 2016-2018

US-Israel Binational Science Foundation, Private, Reviewer, 2016

**PUBLICATIONS**

**Peer-Reviewed Original Research Articles**

1. Miglierina R. Some applications of microspheres in flow cytometry. *Biol Cell* 58(2):127-30, 1986. PMID: 2950951.
2. Leppik IE. Variability of phenytoin, carbamazepine and valproate concentrations in a clinic population. *Epilepsy Res Suppl* 1:85-90, 1988. PMID: 3149581.
3. **Davies MA**, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. *Cancer Res* 58(23):5285-90, 12/1998. PMID: 9850049.
4. Delehedde M, Cho SH, Sarkiss M, Brisbay S, **Davies MA**, El-Naggar AK, McDonnell TJ. Altered expression of bcl-2 family member proteins in nonmelanoma skin cancer. *Cancer* 85(7):1514-22, 4/1999. PMID: 10193941.
5. **Davies MA**, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. *Cancer Res* 59(11):2551-6, 6/1999. PMID: 10363971.
6. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, **Davies MA**, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitich K, Mills GB. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. *Oncogene* 18(50):7034-45, 11/1999. PMID: 10597304.
7. Tanaka M, Koul D, **Davies MA**, Liebert M, Steck PA, Grossman HB. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. *Oncogene* 19(47):5406-5412, 11/2000. PMID: 11103942.
8. Beresford SA, **Davies MA**, Gallick GE, Donato NJ. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells. *J Interferon Cytokine Res* 21(5):313-22, 5/2001. PMID: 11429162.
9. Koul D, Parthasarathy R, Shen R, **Davies MA**, Jasser SA, Chintala SK, Rao JS, Sun Y, Benveniste EN, Liu TJ, Yung WK. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. *Oncogene* 20(46):6669-78, 10/2001. PMID: 11709701.
10. **Davies MA**, Kim SJ, Parikh NU, Dong Z, Bucana CD, Gallick GE. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. *Clin Cancer Res* 8(6):1904-1914, 2002. PMID: 12060635.

11. Koul D, Jasser SA, Lu Y, **Davies MA**, Shen R, Shi Y, Mills GB, Yung WK. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. *Oncogene* 21(15):2357-2364, 2002. PMID: 11948419.
12. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, **Davies MA**, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Puzstai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. *Cancer Res* 68(15):6084-91, 8/2008. PMID: 18676830.
13. **Davies MA**, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB. A novel AKT3 mutation in melanoma tumours and cell lines. *Brit J Cancer* 99(8):1265-1268, 9/2008. PMID: 18813315.
14. O'Reilly KE, Warycha M, **Davies MA**, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, Mills G, Osman I. Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma. *Clin Cancer Res* 15(8):2872-2878, 4/2009. e-Pub 3/2009. PMID: 19336517.
15. Aziz SA, **Davies MA**, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. *Clin Cancer Res* 15(9):3029-36, 5/2009. e-Pub 4/2009. PMID: 19383818.
16. Vasudevan KM\*, Barbie DA\*, **Davies MA\***, Rabinovsky R, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, McNear CJ, Sandy P, Hoesch S, Sheng Q, Gupta P, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer \*Featured on Cover. *Cancer Cell* 16(1):21-32, 7/2009. PMID: 19573809 (**\*contributed equally**).
17. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Priol S, Pavan GM, Fermeglia M, Vashisht Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, **Davies MA**. Activity of Dasatinib Against L576P KIT Mutant Melanoma: Molecular, Cellular, and Clinical Correlates. *Mol Cancer Ther* 8(8):2079-85, 8/2009. e-Pub 8/2009. PMID: 19671763.
18. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, Kim KB, Woodman S, **Davies MA**, Plaza JA, Nash JW, Prieto VG, Lazar AJ, Ivan D. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. *Mod Pathol* 22(11):1446-56, 11/2009. e-Pub 8/2009. PMID: 19718013.
19. **Davies MA**, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. *Clin Cancer Res* 15(24):7538-7546, 12/2009. e-Pub . PMID: 19996208.
20. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, Lee JS, **Davies MA**. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. *Mol Cancer Ther* 9(2):257-67, 2/2010. e-Pub 2/2010. PMID: 20124458.
21. Ding Z, Liang J, Li J, Lu Y, Ariyaratna V, Lu Z, **Davies MA**, Westwick JK, Mills GB. Physical Association of PDK1 with AKT1 is Sufficient for Pathway Activation Independent of Membrane Localization and Phosphatidylinositol 3 Kinase. *PLoS One* 5(3):e9910, 3/2010. PMID: 20361045.
22. Sikora AG, Gelbard A, **Davies MA**, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. *Clin Cancer Res* 16(6):1834-44, 3/2010. PMID: 20215556.
23. Altman MK, Gopal V, Jia W, Yu S, Hall H, Mills GB, McGinnis AC, Bartlett MG, Jiang G, Madan D, Prestwich GD, Xu Y, **Davies MA**, Murph MM. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. *Mol Cancer* 9:140, 6/2010. PMID: 20529378.

24. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, **Davies MA**. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. *Cancer Res* 70(21):8736-8747, 11/2010. PMID: 20959481.
25. Wei X, Prickett TD, Vilorio CG, Molinolo A, Lin JC, Cardenas-Navia I, Cruz P, NISC Comparative Sequencing Program, Rosenberg SA, **Davies MA**, Gershenwald JE, López-Otín C, Samuels Y. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. *Mol Cancer Res* 8(11):1513-25, 11/2010. PMID: 21047771.
26. Hennessy BT, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, **Davies MA**, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen Dale AL, Mills GB. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. *Clin Proteomics* 6(4):129-151, 12/2010. PMID: 21691416.
27. Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, **Davies MA**, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM. In vitro studies of dasatinib, its targets and predictors of sensitivity. *Pigment Cell Melanoma Res* 2(24):386-9, 4/2011. PMID: 21320292.
28. **Davies MA**, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A. Prognostic Factors for Survival in Melanoma Patients with Brain Metastases. *Cancer - Am Cancer Soc* 117(8):1687-96, 4/2011. PMID: 20960525.
29. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, NISC Comparative Sequencing Program, Stemke-Hale K, **Davies MA**, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. *Nat Genet* 43(5):442-6, 5/2011. PMID: 21499247.
30. Bedikian AY, Silverman JA, Papadopolous NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsji J, **Davies MA**, Hwu P. Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients with Impaired Liver Function. *J Clin Pharmacol* 51(8):1205-12, 8/2011. PMID: 20978276.
31. Prickett TD, Wei X, Teer J, Cherukuri PF, Lin, JC, Molinolo A, Rosenberg SA, **Davies MA**, Gershenwald JE, Stemke-Hale K, Margulies EH, Samuels Y. Exon Capture Analysis of G-Protein Coupled Receptors Reveals Activating Mutations in GRM3 in Melanoma. *Nat Genet* 43(11):1119-26, 9/2011. PMID: 21946352.
32. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsji J, **Davies MA**, McIntyre S, Hwu P. Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma. *Am J Clin Oncol* 34(6):603-10, 12/2011. PMID: 21150567.
33. Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, Hwu P, Atkins MB, **Davies MA**. Correlation of NRAS mutations with clinical response to high dose IL-2 in patients with advanced melanoma. *J Immunother* 35(1):66-72, 1/2012. PMID: 22130161.
34. **Davies MA**, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng C, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. *Clin Cancer Res* 18(4):1120-8, 2/2012. PMID: 22223528.
35. Deng W, Yennu-Nanda VG, Woodman SE, **Davies MA**. Role and therapeutic potential of PI3K-mTOR in de novo resistance to BRAF inhibition. *Pigment Cell Melanoma Res* 25(2):248-58, 3/2012. PMID: 22171948.
36. Mu H, Calderone TL, **Davies MA**, Prieto VG, Wang H, Mills GB, Bar-Eli M, Gershenwald JE. Lysophosphatidic Acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. *Am J Pathol* 180(5):2170-81, 5/2012. PMID: 22465753.
37. Al-Zaid T, Ditelberg JS, Prieto VG, Lev D, Luthra R, **Davies MA**, Diwan AH, Wang WL, Lazar AJ. Trichilemmomas show loss of PTEN in Cowden Syndrome but only rarely in sporadic tumors. *J Cutan Pathol* 39(5):493-9, 5/2012. PMID: 22486434.
38. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Placc C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D,

- Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, **Davies MA**, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L. A Landscape of Driver Mutations in Melanoma. *Cell* 150(2):251-263, 7/2012. PMID: 22817889.
39. Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, **Davies MA**, Grimm EA. Association of activated c-Met with NRAS-mutated human melanomas: A possible avenue for targeting. *Int J Cancer* 131(2):E56-65, <http://onlinelibrary.wiley.com/doi/10.1002/ijc.26487/abstract;jsessionid=8C962BAF95B31E3A7308AD99279BC1B1.d01t03>, 7/2012. PMID: 22020736.
  40. Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, **Davies MA**, Priebe W, Heimberger AB. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. *Int J Cancer* 131(1):8-17, 7/2012. PMID: 21792892.
  41. Khalili JS, Yu X, Wang J, Hayes BC, **Davies MA**, Lizée G, Esmaeli B, Woodman SE. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ and GNA11 dependant manner. *Clin Cancer Res* 18(16):4345-55, 8/2012. PMID: 22733540.
  42. Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Hwu P, Kim KB, Lazar AJ, **Davies MA**. NRAS mutation status is an independent prognostic factor in Metastatic Melanoma. *Cancer - Am Cancer Soc* 118(16):4014-23, 8/2012. PMID: 22180178.
  43. Alvarado G, Noor R, Basset R, Papadopoulos NE Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, **Davies MA**. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. *Melanoma Res* 22(4):310-5, 8/2012. PMID: 22584956.
  44. Kim J, Lazar AJ, **Davies MA**, Homsy J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. *J Cutan Pathol* 39(9):821-5, 9/2012. PMID: 22809251.
  45. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, **Davies MA**, Wargo JA, Hwu P, Lizée G. Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. *Clin Cancer Res* 18(19):5329-40, 10/2012. PMID: 22850568.
  46. Beasley GM, Coleman AP, Raymond A, Sanders G, Selim MA, Peterson BL, Brady MS, **Davies MA**, Augustine C, Tyler DS. A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. *Ann Surg Oncol* 19(12):3896-905, 11/2012. PMID: 22549288.
  47. Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, **Davies MA**, Hwu P, Atkins MB, Sullivan RJ. Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2. *J Immunother* 35(9):711-715, 11/2012. PMID: 23090080.
  48. Long GV, Trefzer U, **Davies MA**, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. *Lancet Oncol* 13(11):1087-95, 11/2012. PMID: 23051966.
  49. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizée G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsy J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, **Davies MA**, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. *Clin Cancer Res* 18(24):6758-70, 15, 12/2012. PMID: 23032743.

50. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Frederick DT, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, **Davies MA**, Radvanyi LG, Overwijk WW, Lizée G, Hwu P. BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Anti-tumor Activity of Adoptive Immunotherapy in Mice. *Clin Cancer Res* 19(2):393-403, 1/2013. PMID: 23204132.
51. Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, Vaughn CS, Lorusso PM, Cohen RB, **Davies MA**, Kim KB. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. *Cancer* 119(4):799-805, 2/2013. PMID: 22972589.
52. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, **Davies MA**, Kopetz S. Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents. *Clin Cancer Res* 19(3):657-667, 2/2013. PMID: 23251002.
53. Greaves WO, Verma S, Patel KP, **Davies MA**, Barkoh BA, Galincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ, Luthra R. Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. *J Mol Diagn* 15(2):220-6, 3/2013. PMID: 23273605.
54. Overman MJ, Zhang J, Kopetz S, **Davies MA**, Jiang Z, Stemke-Hale K, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary G, Broom B, Wang H. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. *PLOS One* 8(6), 6/2013. PMID: 23776447.
55. Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, Lin JC, Davis S, Simhadri VL, Jha S, Katagiri N, Gotea V, Teer JK, Wei X, Morken MA, Bhanot UK, NISC Comparative Sequencing Program, Chen G, Elnitski LL, **Davies MA**, Gershenwald JE, Carter H, Karchin R, Robinson W, Robinson S, Rosenberg SA, Collins FS, Parmigiani G, Komar AA, Kimchi-Sarfaty C, Hayward NK, Margulies EH, Samuels Y. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. *Proc Natl Acad Sci U S A* 110(33):13481-6, 8/2013. PMID: 23901115.
56. Bowles DW, Ma WW, Senzer N, Brahmer JR, Adjei AA, **Davies MA**, Lazar AJ, Vo A, Peterson S, Walker L, Hausman D, Rudin CM, Jimeno A. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. *Br J Cancer* 109(5):1085-92, 9/2013. PMID: 23942080.
57. Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, D'Andrea K, O'Day S, Infante JR, Falchook GS, Arkenau HT, Millward M, Brown MP, Pavlick A, **Davies MA**, Ma B, Gagnon R, Curtis CM, Lebowitz PF, Kefford RF, Long GV. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). *Clin Cancer Res* 19(17):4868-78, 9/2013. PMID: 23833299.
58. Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, **Davies MA**. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. *Cancer* 119(21):3821-9, 11/2013. PMID: 23922205.
59. Lopez-Rivera E, Jayaraman P, Parikh F, **Davies MA**, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso JA, Sikora AG. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. *Cancer Res* 74(4):1067-87, 2/2014. PMID: 24398473.
60. Prickett TD, Zerlanko B, Gartner JJ, Parker SC, Dutton-Regester K, Lin JC, Teer JK, Wei X, Jiang J, NISC Comparative Sequencing Program, Chen G, **Davies MA**, Gershenwald JE, Robinson W, Robinson S, Hayward NK, Rosenberg SA, Margulies EH, Samuels Y. Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin. *J Invest Dermatol* 134(2):452-60, 2/2014. PMID: 24008424.
61. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, **Davies MA**, Herlyn M, Winkler J, Koumenis C, Amaravadi RK. Targeting ER stress induced-autophagy overcomes resistance to BRAF inhibition in melanoma. *J Clin Invest* 124(3):1406-17, 3/2014. PMID: 24569374.

62. Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, **Davies MA**, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Scolyer RA, Mann GJ, Thompson JF, Hayward NK, Samuels Y. A highly recurrent RPS27 5'UTR mutation in melanoma. *Oncotarget* 5(10):2912-7, 5/2014. PMID: 24913145.
63. Kugel CH, Hartsough EJ, **Davies MA**, Setiady YY, Aplin AE. Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor. *Cancer Res* 74(15):4122-32, 8/2014. PMID: 25035390.
64. Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu WJ, Bedikian AY, **Davies MA**, Woodman SE, Hwu P. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon- $\alpha$  in patients with metastatic melanoma. *Melanoma Res* 24(4):342-8, 8/2014. PMID: 24743052.
65. Watson IR, Li L, Cabeceiras PK, Mahdavi M, Gutschner T, Genovese G, Wang G, Fang Z, Tepper JM, Stemke-Hale K, Tsai KY, **Davies MA**, Mills GB, Chin L. The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF. *Cancer Res* 74(17):4845-4852, 9/2014. PMID: 25056119.
66. Bucheit AD, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D, Fox P, Bassett R, Hwu P, Gershenwald JE, Lazar AJ, **Davies MA**. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. *Clin Cancer Res* 20(21):5527-36, 11/2014. PMID: 25165098.
67. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, Pereira CG, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, **Davies MA**. Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. *Clin Cancer Res* 20(21):5537-46, 11/2014. PMID: 24803579.
68. Gopal YN, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, **Davies MA**. Inhibition of mTORC1/2 overcomes PGC1 $\alpha$  and OxPhos-mediated resistance. *Cancer Res* 74(23):7037-47, 12/2014. PMID: 25297634.
69. Baladandayuthapani V, Talluri R, Ji Y, Coombes KR, Lu Y, Hennessy BT, **Davies MA**, Mallick BK. Bayesian sparse graphical models for classification with application to protein expression data. *Ann Appl Stat* 8(3):1443-1468, 2014. PMID: 26246866.
70. Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, **Davies MA**, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale. *PLoS One* 9(7):e101286, 2014. e-Pub 7/2014. PMID: 24983357.
71. Curry JL, **Davies MA**, Calderone TL, Nathanson K, Prieto VG, Gershenwald JE. Tissue resources for clinical use and marker studies in melanoma. *Methods Mol Biol* 1102:679-95, 2014. PMID: 24259006.
72. Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, **Davies MA**, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. mTORC1 activation blocks Braf V600E - induced growth arrest, but is insufficient for melanoma formation. *Cancer Cell* 27(1):41-56, 1/2015. PMID: 25584893.
73. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, **Davies MA**. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. *J Invest Dermatol* 135(2):508-15, 2/2015. PMID: 25148578.
74. Turley RS, Tokuhisa Y, Toshimitsu H, Lidsky ME, Padussis JC, Fontanella A, Deng W, Augustine CK, Beasley GM, **Davies MA**, Dewhirst MW, Tyler DS. Targeting N-cadherin Increases Vascular Permeability and Differentially Activates AKT in Melanoma. *Ann Surg* 261(2):368-77, 2/2015. PMID: 24646553.

75. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, **Davies MA**, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical actionability enhanced through deep targeted sequencing of solid tumors. *Clin Chem* 61(3):544-53, 3/2015. PMID: 25626406.
76. Ju Z, Liu W, Roebuck PL, Siwak DR, Zhang N, Lu Y, **Davies MA**, Akbani R, Weinstein JN, Mills GB, Coombes KR. Development of a robust classifier for quality control of reverse-phase protein arrays. *Bioinformatics* 31(6):912-8, 3/2015. PMID: 25380958.
77. Scortegagna M, Lau E, Zhang T, Feng Y, Sereduk C, Yin H, De SK, Meeth K, Platt JT, Langdon CG, Halaban R, Pellecchia M, **Davies MA**, Brown K, Stern DF, Bosenberg M, Ronai ZA. PDK1 and SGK3 contribute to the growth of BRAF mutant melanomas and are potential therapeutic targets. *Cancer Res* 75(7):1399-412, 4/2015. PMID: 25712345.
78. Stockman DL, Curry JL, Torres-Cabala CA, Watson IR, Siroy AE, Bassett RL, Zou L, Patel KP, Luthra R, **Davies MA**, Wargo JA, Routbort MA, Broaddus RR, Prieto VG, Lazar AJ, Tetzlaff MT. Use of Clinical Next-Generation Sequencing To Identify Melanomas Harboring SMARCB1 Mutations. *J Cutan Pathol* 42(5):308-17, 5/2015. PMID: 25754356.
79. Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodriguez-Cruz T, Liu S, Whittington M, Deng W, Li F, Bernatchez C, Radvanyi LG, **Davies MA**, Hwu P, Lizée G. BRAF(V600E) co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma. *Cancer Immunol Res* 3(6):602-9, 6/2015. PMID: 25795007.
80. Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. *Cell* 161(7):1681-96, 6/2015. PMID: 26091043.
81. Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, **Davies MA**, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJ. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. *Clin Cancer Res* 21(11):2644-51, 6/2015. PMID: 25695693.
82. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, **Davies MA**, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. *J Natl Cancer Inst* 107(7), 7/2015. PMID: 25863335.
83. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, **Davies MA**, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E immunohistochemical expression pattern as a surrogate of BRAF mutation status in 154 patients with advanced melanoma. *Hum Pathol* 46(8):1101-10, 8/2015. PMID: 26058727.
84. Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, **Davies MA**, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3/ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas. *Cancer Res* 75(15):3554-67, 9/2015. PMID: 26206558.
85. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, **Davies MA**, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. *J Clin Oncol* 33(25):2753-62, 9/2015. PMID: 26014291.
86. Vu HL, Rosenbaum S, Purwin TJ, **Davies MA**, Aplin AE. RAC1 P29S regulates PD-L1 expression in melanoma. *Pigment Cell Melanoma Res* 28(5):590-8, 9/2015. PMID: 26176707.
87. Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, **Davies MA**, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL. AKT1 Activation Promotes Development of Melanoma Metastases. *Cell Rep* 13(5):898-905, 11/2015. PMID: 26565903.
88. Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, **Davies MA**, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J,

- Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. *J Transl Med* 13(1):374, 11/2015. PMID: 26619946.
89. Glitza IC, Haymaker C, Bernatchez C, Vence LM, Rohlfs ML, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Woodman SE, Patel S, Hwu WJ, Radvanyi L, **Davies MA**, Papadopoulos NE, Hwu P. Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: A case report. *Cancer Immunol Res* 3(11):1201-6, 11/2015. PMID: 26216417.
  90. Hong D, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, **Davies MA**, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. *Clin Cancer Res* 21(21):4801-10, 11/2015. PMID: 26169970.
  91. Feng Y, Pinkerton AB, Hulea L, Zhang T, **Davies MA**, Grotegut S, Cheli Y, Yin H, Lau E, Kim H, De SK, Barile E, Pellecchia M, Bosenberg M, Li JL, James B, Hassig CA, Brown KM, Topisirovic I, Ronai ZA. SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. *Cancer Res* 75(75):5211-5218, <http://cancerres.aacrjournals.org/content/75/24/5211.abstract>, 12/2015. PMID: 26603897.
  92. Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, **Davies MA**, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK. Role of Increased n-acetylaspartate Levels in Cancer. *J Natl Cancer Inst* 108(6):djv426, 1/2016. PMID: 26819345.
  93. Roszik J, Wu CJ, Siroy AE, Lazar AJ, **Davies MA**, Woodman SE, Kwong LN. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. *Sci Rep* 6:19649, 1/2016. PMID: 26787600.
  94. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, **\*Davies MA**, **\*Hwu P**. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. *Cancer Discov* 6(2):202-16, 2/2016. PMID: 26645196 (**\*contributed equally**).
  95. Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, **Davies MA**, Berger AC, Aplin AE. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. *J Invest Dermatol* 136(2):453-63, 2/2016. PMID: 26967478.
  96. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, **Davies MA**, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. *Oncoimmunology* 5(3):e1136044, 3/2016. PMID: 27141370.
  97. Tsai WB, Long Y, Park JR, Chang JT, Liu H, Rodriguez-Canales J, Savaraj N, Feun LG, **Davies MA**, Wistuba II, Kuo MT. Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents. *Oncogene* 35(13):1632-42, 3/2016. PMID: 26096933.
  98. Sholl LM, Andea A, Bridge JA, Cheng L, **Davies MA**, Ehteshami M, Gangadhar TC, Kamel-Reid S, Lazar A, Raparia K, Siroy A, Watson KL, Members of Cancer Biomarker Reporting Committee, College of American Pathologists. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. *Arch Pathol Lab Med* 140(4):355-7, 4/2016. PMID: 26340412.



99. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, **Davies MA**, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. *Ann Oncol* 27(5):795-800, 5/2016. PMID: 26787237.
100. Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, **Davies MA**, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. *J Clin Invest* 126(5):1834-56, 5/2016. PMID: 27043285.
101. Ekmekcioglu S, **Davies MA**, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma. *Clin Cancer Res* 22(12):3016-24, 6/2016. PMID: 26783288.
102. Goedert L, Pereira CG, Roszik J, Praça JR, Cardoso C, Chen G, Deng W, Yennu-Nanda VG, Silva WA, **Davies MA**, Espreadico EM. RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma. *Oncotarget* 7(24):36711-36718, 6/2016. PMID: 27167340.
103. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, **Davies MA**, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The State of Melanoma: Challenges and Opportunities. *Pigment Cell Melanoma Res* 29(4):404-16, 7/2016. PMID: 27087480.
104. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, **Davies MA**, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. *Cancer Discov* 6(8):827-37, 8/2016. PMID: 27301722.
105. Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, **Davies MA**. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. *JAMA Oncol* 2(8):1056-64, 8/2016. PMID: 27124486.
106. Teh JL, Purwin TJ, Greenawalt EJ, Chervoneva I, Goldberg A, **Davies MA**, Aplin AE. An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma. *Cancer Res* 76(18):5455-66, 9/2016. PMID: 27488531.
107. Tetzlaff MT, Singh RR, Seviour EG, Curry JL, Hudgens CW, Bell D, Wimmer DA, Ning J, Czerniak BA, Zhang L, **Davies MA**, Prieto VG, Broaddus RR, Ram P, Luthra R, Esmaeli B. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. *J Pathol* 240(1):84-95, 9/2016. PMID: 27287813.
108. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, **Davies MA**, Woodman SE. Novel

- algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. *BMC Med* 14(1):168, 10/2016. PMID: 27776519.
109. Tripp MK, Gershenwald JE, **Davies MA**, Garcia J, Gritz ER, Hawk ET, Peterson SK. Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. *JAMA Dermatol.* e-Pub 11/2016. PMID: 27829081.
  110. Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, **Davies MA**, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. *J Transl Med* 14(1):313, 11/2016. PMID: 27846884.
  111. Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, **\*Davies MA**, Kluger HM\*. Melanoma Central Nervous System Metastases: Current Approaches, Challenges, and Opportunities. *Pigment Cell Melanoma Res* 29(6):627-642, 11/2016. PMID: 27615400 (**\*contributed equally**).
  112. Krepler C, Xiao M, Samanta M, Vultur A, Chen HY, Brafford P, Reyes-Urbe PI, Halloran M, Chen T, He X, Hristova D, Liu Q, Samatar AA, **Davies MA**, Nathanson KL, Fukunaga-Kalabis M, Herlyn M, Villanueva J. Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. *Oncotarget* 7(44):71211-71222, 11/2016. PMID: 27655717.
  113. McQuade JL, Posada LP, Lecagoonporn S, Cain S, Bassett RL, Patel SP, Hwu WJ, Hwu P, **Davies MA**, Bedikian AY, Amaria RN. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. *Melanoma Res* 26(6):604-608, 12/2016. PMID: 27540836.
  114. Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, **Davies MA**. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. *Lancet Oncol* 17(12):1621-1754, 12/2016. PMID: 27864013.
  115. Vettus E, Draper D, **Davies MA**. Metastatic Melanoma Responding to Combination Chemotherapy and Immunotherapy After Progression on Ipilimumab and Nivolumab Immunotherapy. *Annals of Clinical Case Reports.* e-Pub 1/2017.
  116. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, **Davies MA**, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. *Ann Oncol* 28(2):368-376, 2/2017. PMID: 27687304.
  117. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, **Davies MA**, Deng W, Gopal YN, Chen G, von Ew EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. *Cancer Cell* 31(2):225-239, 2/2017. PMID: 28196595.
  118. Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, Thompson MA, Puzanov I, Greer JP, Rapisuwon S, Postow M, **Davies MA**, Eroglu Z, Johnson D. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. *J Immunother Cancer* 5:8, 2/2017. PMID: 28239462.
  119. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, **Davies MA**, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. *Sci Transl Med* 9(379), 3/2017. PMID: 28251903.

120. Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, **Davies MA**. Clinicopathological features and clinical outcomes associated with TP53 and BRAF (Non-V600) mutations in cutaneous melanoma patients. *Cancer* 123(8):1372-1381, 4/2017. PMID: 27911979.
121. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, **Davies MA**, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. *NPJ Genom Med* 2. e-Pub 4/2017. PMID: 28819565.
122. Fiziev P, Akdemir KC, Miller JP, Keung EZ, Samant NS, Sharma S, Natale CA, Terranova CJ, Maitituoheti M, Amin SB, Martinez-Ledesma E, Dhamdhare M, Axelrad JB, Shah A, Cheng CS, Mahadeshwar H, Seth S, Barton MC, Protopopov A, Tsai KY, **Davies MA**, Garcia BA, Amit I, Chin L, Ernst J, Rai K. Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. *Cell Rep* 19(4):875-889, 4/2017. PMID: 28445736.
123. Nagarajan P, Curry JL, Ning J, Piao J, Torres-Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, **Davies MA**, Malpica A, Prieto VG, Tetzlaff MT. Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases. *Clin Cancer Res* 23(8):2093-2104, 4/2017. PMID: 27864417.
124. **Davies MA**, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. *Lancet Oncol* 18(7):863-873, July, 7/2017. PMID: 28592387.
125. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, **Davies MA**, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Ann Oncol* 28(7):1631-1639, 7/2017. PMID: 28475671.
126. Fang S, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, **Davies MA**, McQuade JL, Sui D, Bassett RL, Reveille JD, Wei Q, Amos CI, Lee JE. Association between body mass index, C-reactive protein levels, and melanoma patient outcomes. *J Invest Dermatol* 137(8):1792-1795, 8/2017. PMID: 28442307.
127. Eskiocak B, McMillan EA, Mendiratta S, Kollipara RK, Zhang H, Humphries CG, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales TI, Eskiocak U, Smith MP, Sudderth J, Komurov K, Deberardinis RJ, Wellbrock C, **Davies MA**, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, Long GV, Kittler R, White MA. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. *Cancer Discov* 7(8):832-851, 8/2017. PMID: 28455392.
128. Reuben A\*, Petaccia de Macedo M\*, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ\*\*, Wargo JA\*\*, **\*\*Davies MA**. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. *Oncoimmunology* 6(12):e1361097, 8/2017. PMID: 29209563 (**\*and\*\*contributed equally**).
129. Iida Y, Ciechanover A, Marzese DM, Hata K, Bustos M, Ono S, Wang J, Salomon MP, Tran K, Lam S, Hsu S, Nelson N, Kravtsova-Ivantsiv Y, Mills GB, **Davies MA**, Hoon DSB.

- Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF- $\kappa$ B Pathway in Melanoma. *Clin Cancer Res* 23(16):4831-4842, 8/2017. PMID: 28389511.
130. Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, **Davies MA**, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. *Eur J Cancer* 82:45-55, 9/2017. PMID: 28648698.
  131. Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaidler H, **Davies MA**, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. *Nat Commun* 8(1):607, 9/2017. PMID: 28928360.
  132. An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, **Davies MA**, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. *Radiother Oncol* 125(1):80-88, 10/2017. PMID: 28916225.
  133. Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, **Davies MA**, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. *Cell Rep* 21(7):1953-1967, 11/2017. PMID: 29141225.
  134. Ndoye A, Budina-Kolomets A, Kugel CH, Webster MR, Kaur A, Behera R, Rebecca VW, Li L, Brafford PA, Liu Q, Gopal YNV, **Davies MA**, Mills GB, Xu X, Wu H, Herlyn M, Nicastri MC, Winkler JD, Soengas MS, Amaravadi RK, Murphy ME, Weeraratna AT. ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma. *Cancer Res* 77(21):5873-5885, 11/2017. PMID: 28887323.
  135. Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, Jiang Y, Wubbenhorst B, Amaravadi R, Bennett J, Beqiri M, Elder D, Flaherty KT, Frederick DT, Gangadhar TC, Guarino M, Hoon D, Karakousis G, Liu Q, Mitra N, Petrelli NJ, Schuchter L, Shannan B, Shields CL, Wargo J, Wenz B, Wilson MA, Xiao M, Xu W, Xu X, Yin X, Zhang NR, **Davies MA**, Herlyn M, Nathanson KL. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. *Cell Rep* 21(7):1936-1952, 11/2017. PMID: 29141224.
  136. Fontanals-Cirera B, Hasson D, Vardabasso C, Di Micco R, Agrawal P, Chowdhury A, Gantz M, de Pablos-Aragoneses A, Morgenstern A, Wu P, Filipescu D, Valle-Garcia D, Darvishian F, Roe JS, **Davies MA**, Vakoc CR, Hernando E, Bernstein E. Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. *Mol Cell* 68(4):731-744.e9, 11/2017. PMID: 29149598.
  137. Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, **Davies MA**, Amaria R, Prieto VG, Curry JL. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy. Report of two patients. *J Cutan Pathol* 44(12):1080-1086, 12/2017. PMID: 28901560.
  138. Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, **Davies MA**, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW. Resistance

- mechanisms to genetic suppression of mutant NRAS in melanoma. *Melanoma Res* 27(6):545-557, 12/2017. PMID: 29076949.
139. Yam C, Xu X, **Davies MA**, Gimotty PA, Morrisette JJ, Tetzlaff MT, Wani K, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas N, Kudchadkar RR, Pavlick A, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC. A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600 mutant solid tumors. *Clin Cancer Res*, 1/2018. PMID: 29051322.
  140. Bédard PL, **Davies MA**, Kopetz S, Juric D, Shapiro GI, Luke JJ, Spreafico A, Wu B, Castell C, Gomez C, Cartot-Cotton S, Mazuir F, Dubar M, Micallef S, Demers B, Flaherty KT. First-in-Human Trial of the PI3K $\beta$ -Selective Inhibitor SAR260301 in Patients with Advanced Solid Tumors. *Cancer* 124(2):315-324, 1/2018. PMID: 28976556.
  141. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Sloane RS, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Sanchez EMR, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, **Davies MA**, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science*, 1/2018. PMID: 29097493.
  142. Hartsough EJ, Kugel CH, Vido MJ, Berger AC, Purwin TJ, Goldberg A, **Davies MA**, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE. Response and resistance to paradox breaking BRAF inhibitor in melanomas in vivo and ex vivo. *Mol Cancer Ther* 17(1):84-95, 1/2018. PMID: 29133617.
  143. Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, **Davies MA**. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. *ESMO Open* 3(1):e000283, 1/2018. PMID: 29387478.
  144. Amaria RN\*, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, **\*\*Davies MA**, Wargo JA\*\*. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. *Lancet Oncol* 19(2):181-193, 2/2018. PMID: 29361468 (**\*and\*\*contributed equally**).
  145. McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, **Davies MA**. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. *Lancet Oncol* 19(3):310-322, 3/2018. PMID: 29449192.
  146. Fang P, Boehling NS, Koay EJ, Bucheit AD, Jakob JA, Settle SH, **Davies MA**, Robinson JP, Sulman EP. Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. *J Neurooncol* 137(1):67-75, 3/2018. PMID: 29198052.
  147. Vera-Aguilera J, Bedikian AY, Bassett RL, Hwu WJ, Kim KB, Qin Y, Cain S, Washington EW, **Davies MA**, Patel SM, Homsy J, Papadopoulos NE, Hwu P, Patel SP. Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver. *Am J Clin Oncol*. e-Pub 3/2018. PMID: 29509591.

148. Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, **Davies MA**, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN. A pre-existing rare PIK3CAE545K subpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. *Cancer Discov* 8(5):556-567, 5/2018. PMID: 29496665.
149. McQuade JL, Daniel CR, **Davies MA**. Body-mass index and metastatic melanoma outcomes - Authors' reply. *Lancet Oncol* 19(5):e227-e228, 5/2018. PMID: 29726386.
150. Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, **Davies MA**, Kwong LN, Levesque MP, Dummer R, Aplin AE. In vivo E2F reporting reveals efficacious schedules of MEK1/2-CDK4/6 targeting and mTOR-S6 resistance mechanisms. *Cancer Discov* 8(5):568-581, 5/2018. PMID: 29496664.
151. Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, **Davies MA**, Heymach JV, Hwu P, Peng W. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. *Cell Metab* 27(5):977-987.e4, 5/2018. PMID: 29628419.
152. Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, Huse JT, Roy-Chowdhuri S, Luthra R, Wistuba II, **Davies MA**. Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease. *J Neuropathol Exp Neurol* 77(7):628-635, 7/2018. PMID: 29873738.
153. Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, **Davies MA**, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M. Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). *J Transl Med* 16(1):207, 7/2018. PMID: 30031393.
154. Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, **Davies MA**, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Lizée G, Woodman SE, Hwu P. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. *Clin Cancer Res* 24(14):3366-3376, 7/2018. PMID: 29496759.
155. Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, **Davies MA**, Prieto VG, Taube JM, Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. *Ann Oncol* 29(8):1861-1868, 8/2018. PMID: 29945191.
156. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, **Davies MA**, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. *Clin Cancer Res* 24(18):4416-4428, 9/2018. PMID: 29848573.
157. Bezrookove V, Nosrati M, Miller JR, De Semir D, Dar AA, Vosoughi E, Vaquero E, Sucker A, Lazar AJ, Gershenwald JE, **Davies MA**, Schadendorf D, Kashani-Sabet M. Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. *Clin Cancer Res* 24(17):4119-4125, 9/2018. PMID: 29776954.
158. Vishnoi M, Boral D, Liu H, Sprouse ML, Yin W, Goswami-Sewell D, Tetzlaff MT, Davies MA, Oliva ICG, Marchetti D. Targeting USP7 identifies a metastasis-competent state within bone marrow-resident melanoma CTCs. *Cancer Res* 78(18):5349-5362, 9/2018. e-Pub 7/2018. PMID: PMC6139068.

159. Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, **Davies MA**, Gershenwald JE, Krepler C, Aplin AE. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. *Cancer Res* 78(19):5680-5693, 10/2018. PMID: 30115691.
160. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, **Davies MA**, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. *J Immunother Cancer* 6(1):103, 10/2018. PMID: 30305177.
161. Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, **Davies MA**, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. *Clin Cancer Res* 24(21):5347-5356, 11/2018. PMID: 29898988.
162. Childress MA, Himmelberg SM, Chen H, Deng W, **Davies MA**, Lovly CM. ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity Cellular phenotypes, and Biochemical Properties. *Mol Cancer Res* 16(11):1724-1736, 11/2018. PMID: 30002191.
163. Amaria RN, Reddy SM, Tawbi HA, **Davies MA**, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nat Med* 24(11):1649-1654, 11/2018. PMID: 30297909.
164. Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, **Davies MA**, Kwong LN, Levesque MP, Dummer R, Aplin AE. Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. *Cancer Discov* 8(12):1654, 12/2018. PMID: 30510016.
165. Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, **Davies MA**, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of Brain Metastases: Prioritization of Therapeutic Targets. *Int J Cancer* 143(11):3019-3026, 12/2018. PMID: 29923182.
166. Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, **Davies MA**, Lazar AJ, Gershenwald JE. Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. *JCO Precis Oncol* 2018, 2018. e-Pub 6/2018. PMID: 31058252.
167. Kluger HM, Margolin KA, **Davies MA**, Long GV, Tawbi HA, Goldberg SB, Chiang VL. Reply to A. Shinde et al. *J Clin Oncol* 37(12):JCO1802463, 4/2019. PMID: 30807233.
168. Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, Stehn CM, Strain SC, Grossmann AH, Duffy KL, Boucher KM, McMahon M, **Davies MA**, Mendoza MC, VanBrocklin MW, Holmen SL. AKT1E17K activates focal adhesion kinase and promotes melanoma brain metastasis. *Mol Cancer Res*. e-Pub 5/2019. PMID: 31138602.
169. Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, **Davies MA**, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. *Pigment Cell Melanoma Res* 32(3):458-469, 5/2019. PMID: 30712316.

170. Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, **Davies MA**. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. *Cancer Discov* 9(5):628-645, 5/2019. PMID: 30787016.
171. Ferguson SD, Bindal S, Bassett RL, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, **Davies MA**, Glitza IC. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). *J Neurooncol* 142(3):499-509, 5/2019. PMID: 30847840.
172. Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, **Davies MA**, Nathanson KL, Kemper K, Peeper DS, Aplin AE. In vivo ERK1/2 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma. *Mol Cancer Ther. e-Pub* 7/2019. PMID: 31270153.
173. Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, **Davies MA**, International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. *Lancet Oncol* 20(7):e378-e389, 7/2019. PMID: 31267972.
174. Ascierto PA, Agarwala SS, Botti G, Budillon A, **Davies MA**, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Zitvogel L, Marincola FM, Masucci G, Caracò C, Thurin M, Puzanov I. Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). *J Transl Med* 17(1):234, 7/2019. PMID: PMC6647284.
175. Vashisht Gopal YN, Gammon ST, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens CW, Fischer GM, Deng W, Reuben A, Peng W, Wang J, Di Francesco ME, Marszalek JR, McQuade JL, Tetzlaff MT, Piwnicka-Worms D, DeBerardinis RJ, **Davies MA**. A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor-resistance in melanoma. *Clin Cancer Res. e-Pub* 8/2019. PMID: 31439581.
176. Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson H, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA, **Davies MA**, Hoos A, Smothers J, Srinivasan R, Paul EM, Yanamandra N, Hwu P. Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3K $\beta$  inhibition in PTEN loss melanoma. *Clin Cancer Res. e-Pub* 8/2019. PMID: 31371342.
177. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, **Davies MA**, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. *N Engl J Med*, 8/2019. PMID: 31166680.
178. Schvartsman G, Ma J, Bassett RL, Haydu LE, Amaria RN, Hwu P, Wong MK, Hwu WJ, Diab A, Patel SP, **Davies MA**, Hamerschlag N, Tawbi HA, Glitza Oliva IC. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. *Cancer. e-Pub* 8/2019. PMID: 31398264.
179. Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, **Davies MA**, Prieto VG, Gershenwald JE, Tetzlaff MT. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. *Mod Pathol. e-Pub* 8/2019. PMID: 31383963.



180. AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, Slater A, Ardley K, Kirby L, Chan KT, Brajanovski N, Smith LK, Rao AD, Lelliott EJ, Kleinschmidt M, Vergara IA, Papenfuss AT, Lau P, Ghosh P, Haupt S, Haupt Y, Sanij E, Poortinga G, Pearson RB, Falk H, Curtis DJ, Stupp P, Devlin M, Street I, **Davies MA**, McArthur GA, Sheppard KE. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. *Proc Natl Acad Sci U S A*. e-Pub 8/2019. PMID: 31439820.
181. Holbrook K, Lutzky J, **Davies MA**, Davis J, Glitza OI, Amari R, Diab A, Patel S, Amin A, Tawbi H., Intracranial Anti-Tumor Activity with Encorafenib Plus Binimetinib in Patients with Melanoma Brain Metastases: A Case Series. *Cancer*. In Press.

#### Invited Articles

1. **Davies MA**, Hennessy B, Mills GB. Point mutations of protein kinases and individualised cancer therapy. *Expert Opin Pharmacother* 7(16):2243-61, 11/2006. PMID: 17059381.
2. **Davies MA**. Metastatic renal cell carcinoma: new standards for first-line therapy? *Molecular Oncology Report*, 2006.
3. Woodman SE, **Davies MA**. Targeting KIT in Melanoma: A Paradigm of Molecular Medicine and Targeted Therapeutics. *Biochem Pharmacol* 80(5):568-74, 9/2010. PMID: 20457136.
4. **Davies MA**, Samuels Y. Analysis of the genome to personalize therapy for melanoma. *Oncogene* 29(41):5545-55, 10/2010. PMID: 20697348.
5. **Davies MA**, Gershenwald JE. Targeted therapy for melanoma - A primer. *Surg Oncol Clin N Am* 20(1):165-80, 1/2011. PMID: 21111965.
6. Chen G, **Davies MA**. Emerging insights into the molecular biology of brain metastases. *Biochem Pharmacol* 3:305-14, 83, 2/2011. PMID: 21946085.
7. **Davies MA**. Regulation, Role, and Targeting of AKT in Cancer. *J Clin Oncol* 29(35):4715-7, 12/2011. PMID: 22025159.
8. Woodman SE, Lazar AJ, Aldape KD, **Davies MA**. New Strategies in Melanoma: Molecular Testing in Advanced Disease. *Clin Cancer Res* 18(5):1195-200, 3/2012. PMID: 22275506.
9. **Davies MA**. The Role of the PI3K-AKT Pathway in Melanoma. *Cancer J* 18(2):142-7, 3/2012. PMID: 22453015.
10. **Davies MA**. Targeted Therapy for Brain Metastases. *Adv Pharmacol* 65:109-42, 2012. PMID: 22959025.
11. Kwong LN, **Davies MA**. Targeted Therapy for Melanoma: Rational Combinatorial Approaches. *Oncogene*, 2/2013. PMID: 23416974.
12. Kwong LN, **Davies MA**. Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma. *Clin Cancer Res* 19(19):5310-9, 10/2013. PMID: 24089444.
13. Bucheit AD, **Davies MA**. Emerging insights into resistance to BRAF inhibitors in melanoma. *Biochem Pharmacol* 87(3):381-9, 2/2014. PMID: 24291778.
14. Shtivelman E, **Davies MA**, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma. *Oncotarget* 5(7):1701-52, 4/2014. PMID: PMC4039128.
15. Chen G, **Davies MA**. Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma. *Hematology/Oncology Clinics of North America* 28(3):523-536, 6/2014. PMID: 24880945.
16. Glitza IC, **Davies MA**. Genotyping of Cutaneous Melanoma. *Chin Clin Oncol* 3(3):27, 9/2014. PMID: 25632386.
17. **Davies MA**. Targeted Therapy for Cutaneous Melanoma: Beyond. *J Patient-Centered Res Rev*. 1(1):12-20, 2014.
18. **Davies MA**. Role and complexity of next-generation sequencing in melanoma. *Cancer Cytopathol* 123(6):329-30, 6/2015. PMID: 25877344.
19. **Davies MA**. Molecular Approaches to Tumor Inhibition in Melanoma. *Clinical Advances in Hematology & Oncology* 13(12), 12/2015. PMID: 27058849.
20. McQuade J, **Davies MA**. Converting biology into clinical benefit: lessons learned from BRAF inhibitors. *Melanoma Manag* 2(3):241-254, 2015. PMID: 26594316.
21. Loghavi S, Routbort MJ, Patel KP, Luthra R, Wang WL, Broaddus RR, **Davies MA**, Lazar AJ. How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments? *J Natl Compr Canc Netw* 14(6):787-92, 6/2016. PMID: 27283170.

22. Glitza Oliva I, Tawbi H, **Davies MA**. Melanoma brain metastases: current areas of investigation and future directions. *Cancer J* 23(1):68-74, Jan/Feb, 1/2017. PMID: 28114258.
23. **Davies MA**, Saiag P, Long GV. Primary medical therapy for BRAFV600E-mutant melanoma brain metastases—is this good enough? *The Lancet Oncology* 18(9):1137-1284, 9/2017.
24. Fischer GM, Vashisht Gopal YN, McQuade JL, Peng W, DeBerardinis RJ, **Davies MA**. Metabolic Strategies of Melanoma Cells: Mechanisms, Interactions with the Tumor Microenvironment, and Therapeutic Implications. *Pigment Cell Melanoma Res* 31(1):11-30, 1/2018. PMID: 29049843.
25. **Davies MA**, Flaherty KT. Melanoma in 2017: Moving treatments earlier to move further forwards. *Nat Rev Clin Oncol* 15(2):75-76, 2/2018. PMID: 29182162.
26. Brastianos P, **Davies MA**, Margolin K, Yu HA. Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. *Am Soc Clin Oncol Educ Book* 39:e59-e69, 1/2019. PMID: 31099629.

#### Editorials

1. **Davies MA**. Special Issue on Melanoma. *Cancer J* 18(2):115-6, 3/2012. PMID: 22453010.
2. **Davies MA**, Kopetz S. Overcoming Resistance to MAPK Pathway Inhibitors. *J Natl Cancer Inst* 105(1):9-10, 1/2013. PMID: 23250957.
3. **Davies MA**. Finding the Right Balance of BRAF Inhibition in Melanoma. *Cancer Discov* 4(5):510-2, 5/2014. PMID: 24795008.
4. **Davies MA**. BRAF in early stage melanoma: rationale for testing and treatment? *Br J Dermatol* 173(1):9-10, 7/2015. PMID: 26174638.
5. McQuade JL, Daniel CR, Hess KR, **Davies MA**. Sex as a predictor of response to cancer immunotherapy. *Lancet Oncology* 19(8):376, 8/2018. PMID: 30102226.

#### Other Articles

N/A

#### Abstracts

1. Joon A, Haydu L, Baladandayuthapani V, Stingo F, Woodman S, Amaria A, Wargo J, shaw K, Meric-Bernstam F, Mills G, Gershenwald J, Hwu P, Lazar a, **Davies MA**. Next generation sequencing of 201 cancer-related genes in melanoma. Society for Melanoma Research 2014 Congress, 11/2014.
2. **Davies MA**, Tawbi H, Ouellet D, Lazar AJF, Weinberg JS, Butterfiels LH, Hamilton RL, Amankulor N, Engh JA, Shivlingham B, Kefford R, Scoyer GV, Mahmood S, Richards-Peterson LE, Swann S, Arbushites MC, Long GV, Kirkwood JM. Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation-positive melanoma with metastases to the brain (BRV116521). *ASCO Annual Meeting 2014 (#TPS9112)*, 2014.
3. **Davies MA**, Martins KD, Sessa T, Swann S. Phase II, open-label study of dabrafenib plus trametinib in patients with BRAF mutation-positive melanoma brain metastases: A GSK-sponsored trial. *ASCO Annual Meeting 2014 (#TPS9106)*, 2014.
4. Glitza IC, Bernatchez C, Bassett RL, Vaughn C, Velasquez P, Diab A, Amaria RN, Yee C, Woodman SE, Patel SP, Kim KB, **Davies MA**, Papadopoulos NE, Bedikian AY, Hwu WJ, Radvanyi LG, Hwu P. Treatment with tumor-infiltrating lymphocytes (TIL) in metastatic melanoma and clinical benefit regardless of site of origin, mutation status, or prior checkpoint blockade. *ASCO Annual Meeting 2014 (#9079)*, 2014.
5. Oba J, Wang WL, Eterovic AK, Stephan CC, Roszik J, Kale CR, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, **Davies MA**, Lazar AJF, Grimm EA, Woodman SE. A global genomic and small molecule inhibitor interrogation of KIT mutant melanoma to reveal underlying biology and novel molecular targets. *ASCO Annual Meeting 2015 (#9039)*, 2015.
6. Roszik J, Joon A, Siroy A, Haydu LE, Stingo F, Baladandayuthapani V, Hwu P, Tetzlaff MT, Wargo JA, Chen JQ, Laszlo GR, Bernatchez C, Gershenwald JE, Lazar AJF, **Davies MA**, Woodman SE. A novel algorithm applicable to cancer next-generation sequencing panels to predict total tumor mutation load and correlation with clinical outcomes in melanoma. *ASCO Annual Meeting 2015 (#9071)*, 2015.

7. Patel SP, L S, Rohlfs ML, Fox PS, Richard J, Iqbal M, Bernzen T, Glitza IC, Papadopoulos NE, Hwu P, **Davies MA**. BRAF and NRAS mutations in Metastatic Melanoma Patients with Leptomeningeal Disease. ASCO Annual Meeting 2015 (#e20079), 2015.
8. Haydu LE, Calderone TL, Miller J, Bassett RL, Joon A, Zhang J, Morgan MB, Shaw KR, Cooper ZA, Burton EM, Siroy A, Wani KM, Stingo F, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Lazar AJF, **Davies MA**, Gershenwald JE,. Comparison of DNA and RNA analyte extraction and melanin removal methods from formalin-fixed paraffin-embedded (FFPE) melanoma. ASCO Annual Meeting 2015 (#e20002), 2015.
9. **Davies MA**, Joon A, Bassett RL, Roszik J, Siroy A, Haydu LE, Chen K, Stingo F, Baladandayuthapani V, Shaw KR, Meric-Bernstam F, Tetzlaff MT, Gershenwald JE, Woodman SE, Lazar AJF,. Demographics, tumor characteristics, and clinical outcomes associated with somatic mutations in 201 cancer-related genes in advanced melanoma patients (pts). ASCO Annual Meeting 2015 (#9057), 2015.
10. Bedard PL, **Davies MA**, Kopetz S, Flaherty KT, Shapiro G, Luke JJ, Spreafico A, Wu B, Gomez C, Cartot-Cotton S, Mazuir F, Micallef S, Demers B, Juric D,. First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737). ASCO Annual Meeting 2015 (#2564), 2015.
11. Kernade J, Roszik J, Joon A, Stingo F, Baladandayuthapani V, Lazar AJF, Woodman SE, **Davies MA**. Identification of potentially actionable mutations in RTKs in melanoma detected by next generation sequencing (NGS). ASCO Annual Meeting 2015 (#9064), 2015.
12. Wargo JA, Amaria RN, Ross MI, Saw RPM, Gershenwald JE, Hwu P, Patel SP, Glitza IC, Diab A, Kefford R, Scolyer RA, Rizos H, Thompson JF, Shannon K, Spillane A, Carlino MS, Guminski A, Simpson L, **Davies MA**, Long GV. Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma. ASCO Annual Meeting 2015 (#TPS9091), 2015.
13. Amaria RN, Bassett RL, Simpson L, Delaney F, Hwu P, Kim K, Hwu WJ, Patel SP, Glitza IC, **Davies MA**, Woodman SE, Yee C, Bedikian AY,. Phase I study of ipilimumab (IPI) with biochemotherapy (BCT) for chemo-naïve patients with metastatic melanoma (MM). ASCO Annual Meeting 2015 (#e20014), 2015.
14. Diab A, Martin A, Simpson L, Algazi AP, Chawla P, Kim DW, Santra S, Patel V, Jadhav N, Abhyankar D, **Davies MA**, Buch SC, Kim K, Daud A. Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma. ASCO Annual Meeting 2015 (#9076), 2015.
15. McQuade JL, Chen G, Panka DJ, Reuben A, Bassett RL, Joon A, Lazar AJF, Tetzlaff MT, Simpson L, Mouton R, Patel SP, Glitza IC, Hwu WJ, Amaria RN, Diab A, Hwu P, Wargo JA, Sullivan RJ, Kim K, **Davies MA**. Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular predictors of response. ASCO Annual Meeting 2015 (#e20051), 2015.
16. Meric-Bernstam F, Brusco L, Daniels MS, Strong LC, Shaw KR, Lu KH, Qi Y, Lara-Guerra H, Litton JK, Zhao H, Eterovic AK, Arun B, Routbort M, Janku F, **Davies MA**, Kopetz S, Mendelsohn J, Mills GB, Chen K. Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. ASCO Annual Meeting 2015 (#1510), 2015.
17. Amaria RN, Wargo JA, Cooper ZA, Tetzlaff MT, Reuben A, **Davies MA**, Gershenwald JE, Jiang H, Austin-Breneman J, Lee JE, Hwu P, Hwu WJ, Cormier JN, Royal RE, Lucci A, Patel SP, Diab A, Glitza IC, Burton EM, Ross MI. Treatment with neoadjuvant BRAF Inhibition Yields Responses in Patients (pts) with High Risk Borderline Resectable Stage III Melanoma. ASCO Annual Meeting 2015 (#e20097), 2015.
18. Amaria RN, Haymaker CL, Bernatchez C, Forget MA, Patel V, Hwu WJ, **Davies MA**, Patel SP, Diab A, Glitza IC, Tawbi HAH, Woodman SE, Wargo JA, Ross MI, Lee JE, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Hwu P. A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM). ASCO Annual Meeting 2016 (#TPS9594), 6/2016.
19. Menzies AM, Johnson DB, Ramanujam S, Atkinson V, Wond ANM, Parker JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ,

- Ribas A, Carlin MS, **Davies MA**, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI). ASCO Annual Meeting 2016 (#9515), 6/2016.
20. Rohlfs, M, Bassett RL, Lacey C, McQual N, Mehta U, John I, Simien R, Tupue S, Dett TK, Glitza IC, Diab A, Amaria RN, Tawbi HAH, **Davies MA**, Hwu WJ, Hwu P, Patel SP. BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma. ASCO Annual Meeting 2016 (#9548), 6/2016.
  21. Sullivan RJ, Barbash Z, Edelheit O, Vidne M, Sosman JA, Flaherty K, **Davies MA**, Johnson DB, Tarcic G. Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram). ASCO Annual Meeting 2016 (#9537), 6/2016.
  22. Flaherty K, **Davies MA**, Grob JJ, Long DV, Nathan PD, Ribas A, Robert C, Schadendorf D, Frederick DT, Hammond MR, Valbuena-Jane J, Mu XJ, Squires M, Jaeger SA, Lane ST, Mookerjee B, Garraway LA. Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. ASCO Annual Meeting 2016 (#9502), 6/2016.
  23. Kim DW, Haydu LE, Joon A, Bassett RL, Siroy A, Tetzlaff MT, Lazar A, Woodman SE, Gershenwald JE, **Davies MA**,. Pathological and clinical features of non-acral cutaneous melanoma (CM) patients (pts) with TP53 and BRAFnon-V600 (NonV600) mutations (mut). ASCO Annual Meeting 2016 (#9535), 6/2016.
  24. Grob JJ, Flaherty K, Long GV, Nathan PD, Schadendorf D, Ribas A, Robert C, Lane SR, Mak C, Legenne P, **Davies MA**. Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials. ASCO Annual Meeting 2016 (#9534), 6/2016.
  25. Barcena E, Trinh V, McIntyre SE, Simien R, Cain S, Diab A, Amaria RN, Patel SP, Glitza IC, Tawbi HAH, **Davies MA**, Hwu WJ. Responses in patients with BRAF V600-mutant metastatic melanoma receiving anti-PD1/PDL1 therapy alone or combined with BRAF inhibitors. ASCO Annual Meeting 2016 (#9546), 6/2016.
  26. Shaw AC, Trinh V, Bassett RL, Glitza IC, Diab A, Amaria RN, Tawbi HAH, **Davies MA**, Hwu WJ, Hwu P, Patel SP,. Retrospective analysis of safety and efficacy of ipilimumab in elderly patients with advanced melanoma. ASCO Annual Meeting 2016 (#9540), 6/2016.
  27. McQuade JL, Haydu LE, Frankian S, Spencer C, Long GV, Brob JJ, Lane SR, Legenne P, Flaherty K, Hwu P, Hess KR, **Davies MA**. The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib. ASCO Annual Meeting 2016 (#9566), 6/2016.
  28. Long GV, Flaherty KT, Schadendorf D, Nathan P, Robert C, Ribas A, **Davies MA**, Lane S, Legos J, Mookerjee B, Grob JJ. Patient Characteristics Associated With  $\geq$  36-month Clinical Benefit With Combination Dabrafenib and Trametinib in COMBI-d. ESMO 2016 Scientific, 10/2016.
  29. Cheng H, Chua V, Purwin TJ, Terai M, Liao C Kageyama K, **Davies MA**, Sato T, Aplin AE. Co-targeting HGF0cMET signaling with MEK inhibitors in metastatic uveal melanoma. 2016 SMR Congress, 11/2016.
  30. McQuade JL, Wang DY, Rai R, Park J, Spencer C, McKean M, Beckermann K, Nahar K, Rubinstein S, Guminski A, Lo S, Sosman JA, Wargo JA, Daniel C, Long GV, Hwu P Hess K, Carlin MS, Menzies A, Johnson DB, **Davies MA**. High body mass index (BMI) is associated with improved clinical outcomes in metastatic melanoma patients treated with anti-PD1: differences by gender. 2016 SMR Congress, 11/2016.
  31. Teh, Jessica Nikbakht N, Purwin TJ, Chervoneva I, **Davies MA**, Aplin AA,. In vivo E2F reporting on efficacious dosing schedule MEK plus CDK inhibition in melanoma. 2016 SMR Congress, 11/2016.
  32. Bindal S, Ferguson S, **Davies MA**, Haydu L, Basset R JR, McCutcheon I, Glitza IC. Leptomeningeal disease (LMD) from metastatic melanoma: a single institution experience and predictors of survival. 2016 SMR Congress, 11/2016.
  33. Long DV, FLaherty KT, Schadendorf D, Nathan P, Robert C, Ribas A, **Davies MA**, Lane S, Legos JJ, Mookerjee B, Grob JJ. Patients characteristics associated with >36-mo clinical

- benefit with combination dabrafenib and trametinib (D+T) in COMBI-d. 2016 SMR Congress, 11/2016.
34. Capparelli, Purwin TJ, **Davies MA**, Aplin AE. Stromal neuregulin-1 modulates the response to MEK inhibitors in WT BRAF/WT NRAS (WT/WT) melanoma. 2016 SMR Congress, 11/2016.
  35. Maria, RN, Prieto P, Tetzlaff M, Diab A, Patel S, Woodman SE, Hwu WJ, Glitza IC, Hwu P, Tawbi H, McQuade JL, Cormier J, Lucci A, Royal R, Lee J, Bassett R, Simpson L, Burton EM, Grimm EA, Reuben A, Spencer C, Gershenwald JE, Ross M, **Davies MA**, Wargo JA. Treatment with neoadjuvant + adjuvant dabrafenib and trametinib (D+T) is associated with improved relapse-free survival (RFS versus standard of care (SOC) therapy in patients with high-risk resectable BRAF-mutant melanoma. 2016 SMR Congress, 11/2016.
  36. **Davies MA**, Robert C, Long GV, Grob JJ, Flaherty KT, Arance A, Sileni-Chiarion V, Thomas L, Lesimple T, Mortier L, Moschos S, Hogg D, Rodas IM, Del Vecchio M, Lebbe C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Saiag P. COMBI-MB: a phase 2 study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant (mut) melanoma brain metastases (MBM). ASCO Annual Meeting 2017, 6/2017.
  37. Wargo JA, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, Andrews MC, Tetzlaff MT, Lazar M, Hwu P, Hwu WJ, Clitza IC, Tawbi HAH, Patel SP, Lee JE, **Davies MA**, Gershenwald JE, Futreal A, Sharma P, Allison JP, Jenq RR. Diversity and composition of the gut microbiome are associated with enhanced responses and improved progression-free survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. ASCO Annual Meeting 2017 (#193510), 6/2017.
  38. Schvartsman G, Ma J, Bassett RL Jr., Haydu LE, Amaria RN, Hwu P, Hwu WJ, Diab A, Patel SP, **Davies MA**, Tawbi HAH. Incidence, patterns of progression and outcomes of melanoma brain metastasis (MBM) during programmed-death 1 inhibitor (PD1i) therapy. ASCO Annual Meeting 2017 (#184700), 6/2017.
  39. Chen WS, Andrews MC, Spencer C, Tawbi HAH, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, **Davies MA**, Gershenwald JE, Sharma P, Allison JP, Futreal A, Wargo JA,. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melanoma (MM) patients (pts). ASCO Annual Meeting 2017 (#193578), 6/2017.
  40. Schadendorf D, Long GV. Grog JJ, Nathan P, Ribas A, **Davies MA**, Flaherty KT, Squires M, Jaeger S, Powell W, Tan P Robert C. PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study. ASCO Annual Meeting 2017, 6/2017.
  41. Menzies AM, Rozeman EA, Amaria RN, Scolyer RA, Tetzlaff MT, Guminski A, **Davies MA**, Blank CU, Wargo JA, Long GV. Preliminary results from the international neoadjuvant melanoma consortium (INMC). ASCO Annual Meeting 2017 (#184819), 6/2017.
  42. McKean MA, Haydu LE, Ma J, Bassett RL Jr., Hwu WJ, Patel, SP, Diab A, Glitza IC, Tawbi HAH, Wong MK, McQuade JL, Hwu P, **Davies MA**, Amaria RN. Prognostic factors for overall survival (OS) in metastatic melanoma (MM) treated with immune checkpoint inhibitors: A single institution study of 696 patients. ASCO Annual Meeting 2017 (#193367), 6/2017.
  43. Janku F, De Groot JF, Javle MM, Prado-Penas M, Shroff RT, Luthra R, Banks K, Lanman RB, Conley AP, Broaddus R, **Davies MA**, Kopetz S, Yung WKA, Heymach J, Fu S, Shaw KR, Meric-Bernstam F. Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations. ASCO Annual Meeting 2017 (#183678), 6/2017.
  44. Patel SP, Glitza IC, Diab A, Amari RN, **Davies MA**, Hwu P, Tawbi HAH, Hwu WJ. The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO + IPI) in patients (pts) with uveal melanoma (UM). ASCO Annual Meeting 2017 (#194043), 6/2017.
  45. Wargo JA, Amaria RN, Prieto PA, Andrews MC, Tetzlaff MT, Futreal PA, Hwu P, Hwu WJ, Glitza IC, Tawbi HAH, Cormier JN, Lee JE, Patel SP, Simpson L, Burton EM, Bassett RL Jr., Ross M, Gershenwald JE, **Davies MA**, Woodman SE. Treatment with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) compared to standard-of-care (SOC) surgery and to

- identify targets to enhance responses in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma. ASCO Annual Meeting 2017 (#194041), 6/2017.
46. de Macedo MP, Wang F, Marzese DM, Hudgens CW, Wani K, Siroy AE, Haydu LE, Danaher P, Merritt C, Ong G, Warren S, Beechem JM, Hoon DSB, Peng W, Tetzlaff M, Lazar A, **Davies MA**. In-depth molecular and immune characterization of melanoma with heterogeneous PTEN expression. World Congress for Melanoma (#2761847), 10/2017.
  47. de Macedo PM, Wang F, Marzese DM, Hudgens CW, Wani K, Haydu LE, Danaher P, Merritt C, Ong G, Warren S, Beechem JM, Hoon DSB, Peng W, Kwong L, Tetzlaff MT, Lazar AJ, **Davies MA**. In-depth Molecular and Immune Characterization of Melanomas with Heterogeneous PTEN Expression. Society of Immunotherapy of Cancer, 11/2017.
  48. Peng W, Xu Chunyu, Melendez B, Jackson H, McKenzi JA, Williams LJ, Chen Y, Mbofung RM, Leahey SE, Lizee G, **Davies MA**, Yanamandra N, Hwu P. OX40 agonist antibody-based combination therapy with PI3K $\beta$  selective inhibitor enhances T cell immunity. AACR Annual Meeting 2018 (#4938), 4/2018.
  49. McQuade, JL, BetofWarner A, Li M, Chon J, Haydu LE, Daniel-MacDougall Carrie, Hess KR, Johnson DB, Menzies AM, Davies, Shoushtari AN. Association of body mass index (BMI) with overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with combined anti-CTLA4 + anti-PD1. ASCO Annual Meeting 2018 (#9562), 6/2018.
  50. Glitza IC, Rohlf ML, Iqbal M, Ricahrd J, Burton E, Duncan S, Brown C, Anderson J, Hwu P, Hwu WJ, Yee C, Patel S, Woodman S, Amaria R, Diab A, Tawbi H, **Davies MA**. A phase I/II study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) For melanoma patients (pts) with leptomeningeal disease (LMD). ESMO 2018 Congress International, 10/2018.
  51. Reddy S, Helmink B, Zhang S, Blando J, Han G, Amaria R, Tawbi HA, **Davies MA**, Hwu P, Lee J, Gershenwald J, Burton E, Hudgens C, Keung E, Gaudreau P, Gopalakrishnan V, Reuben A, Andrews MC, Spencer C, Allison J, Sharma P, Tetzlaff MT, Wang L, Wargo J. B cell signature predicts survival in melanoma and response to immune checkpoint blockade (ICB). 2018 SMR International Congress Meeting, 10/2018.
  52. Tiago M, Capparelli C, Erkes D, Purwin TD, **Davies MA**, Aplin AE. BET proteins inhibition to optimize BRAFi/MEKi therapy for mutant BRAF melanoma. 2018 SMR Congress International Meeting, 10/2018.
  53. Fischer GM, Yennu-Nanda VG, Tetzlaff MT, Lazar AJ, Carapeto F, de Macedo MP, Hudgens C, Holmen SL, Kircher DA, Knighton B, **Davies MA**. Oxidative Phosphorylation (OXPHOS): A Feature, Driver, and Therapeutic Target in Melanoma Brain Metastases (MBMs). 2018 SMR International Congress Meeting, 10/2018.
  54. Andrews MC, Chen S, Prieto P, Marszalek J, Hudgens C, Tetzlaff MT, Amaria R, Gershewald J, **Davies MA**, Arur S, Heffernan TP, Wargo J. Sexual dimorphism in response to BRAF mut melanoma target therapy. 2018 SMR International Congress Meeting, 10/2018.
  55. McQuade JL, Gopalakrishnan V, Spencer C, Andrews MC, Helmink B, Cogdill AP, Sirmans E, Haydu LE, Posada E, Burton E, Glitza I, Amaria R, Patel S, Diab A, Wong M, Tawbi HA, Hwu WJ, **Davies MA**, Hwu P, Jenq R, Nelson K, Daniel CR, Cohen L, Wargo J. The gut microbiome of melanoma patients is distinct from that of healthy individuals and is impacted by probiotic and antibiotic use. 2018 SMR International Congress Meeting, 10/2018.
  56. Carapeto FCL, Fischer GM, Joon AY, Chen H, Haydu L, Lee S, Saul M, Appana S, Thompson JF, Mann GJ, McQuade JL, Lazar AJ, Kirkwood J, Scolyer RA, Long GV, **Davies MA**. Analysis of molecular and immune features that correlate with serum lactate dehydrogenase (LDH) levels in patients (pts) with metastatic melanoma. AACR Special Conference on Melanoma: From Biology to Target, 1/2019.
  57. Fischer GM, Kotrotsou A, Ahmed S, O'Neal P, Sahnoune I, Yennu-Nanda VG, Hudgens C, Knighton B, Colen R, Tetzlaff MT, **Davies MA**. Molecular, immunological, metabolic, and radiomic associations of oxidative phosphorylation (OXPHOS) in melanoma brain metastases (MBMs). AACR Special Conference on Melanoma: From Biology to Target, 1/2019.
  58. Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Aung PA, Ivan D, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, **Davies MA**, Prieto VG, Gershenwald JE. Prognostic Model for Disease Specific Survival in

- Anorectal Melanoma. AACR Special Conference on Melanoma: From Biology to Target, 1/2019.
59. Yennu Nanda VG, Gammon S, Prasad R, Knighton B, Pisaneschi F, Feng N, Williams L, Pramanik S, Sudderth J, Sui D, Fischer GM, Deng W, Peng W, Wang J, McQuade JL, Tetzlaff M, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, **Davies MA**. A novel mitochondrial inhibitor overcomes resistance to BRAF and MEK inhibition in melanoma. 2019 Melanoma Research Alliance 11th Annual Scientific Retreat, 2/2019.

#### Book Chapters

1. **Davies MA**. PTEN, a tumor suppressor gene frequently mutated in glioblastomas. In: *Genomic and Molecular Neuro-Oncology*. Ed(s) Wei Zhang and Gregory N. Fuller. Jones and Bartlett: Sudbury, MA, 47-61, 2004.
2. **Davies MA**, Patel S, Kim K. Targeted Therapy in Melanoma. In: *Targeted Therapy in Cancer*, 1. Ed(s) Kurzrock R, Markman M. Humana Press: Totowa, NJ, 183-211, 2008. PMID: 978-1-60327-423-4.
3. Kim KB, **Davies MA**, Rapini RP, Hwu P, Bedikian AY. Malignant Melanoma. In: *The MD Anderson Manual of Medical Oncology, Second Edition*, 2nd. McGraw Hill: China, 1077-1109, 2011.
4. Ahmed KB, **Davies MA**. New Molecular Targets for Systemic Therapy of Melanoma. In: *Research on Melanoma - A Glimpse into Current Directions and Future Trends*,. Ed(s) M Murph. InTech - Open Access Publisher, 161-180, 2011. PMID: 978-953-307-293-7.
5. Kupferman ME, **Davies MA**. Melanoma of the Head and Neck: General Principles and Management. In: *Head and Neck Cancer A Multidisciplinary Approach*, 4th. Wolters Kluwer Lippincott Williams & Wilkins, 672-691, 2013. PMID: 978-1-45114487-1.
6. **Davies MA**, Garraway LA. Molecular Biology of Cutaneous Melanoma. In: *Cancer Principles & Practice of Oncology*, 10th. Ed(s) VT Devita Jr, TS Lawrence, SA Rosenberg. Wolters Kluwer, 1337-1345, 2015. PMID: 978-1-4511-9294-0.
7. **Davies MA**, Garraway LA. Molecular Biology of Cutaneous Melanoma. In: *Cancer: Principles and Practice of Oncology*. Primer of the molecular biology of cancer, 2nd edition. Ed(s) VT DeVita Jr., TS Lawrence, SA Rosenberg. Wolters Kluwer, 308 - 320, 2015. PMID: 978-1496310637.
8. **Davies MA**. Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma. In: *BRAF Targets in Melanoma*. 82. Ed(s) Sullivan RJ. Humana Press: Maryland, 105.135, 2015. PMID: 978-1-4939-2142-3.
9. Glitza IC, Heimberger AB, Sulman EP, **Davies MA**. Prognostic factors for survival in melanoma patients with brain. In: *Brain Metastases from Primary Tumors*. 3. Ed(s) M. A. Hayat. Academic Press: New York, 267-297, 2016. PMID: 978-0-12-803508-5.
10. Siroy AE, **Davies MA**, Lazar AJ. The PI3K-AKT Pathway in Melanoma. In: *Genetics of Melanoma*. Ed(s) Torres-Cabala C, Curry JL. Cancer Genetics: New York, 165-180, 2016. PMID: 978-1-4939-3554-3.
11. Margolin K, **Davies MA**, Kluger H, Tawbi H. Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. In: *Cutaneous Melanoma*, 6th. Ed(s) Balch, C, Gershenwald J, Thompson J, Atkins M, Kirkwood J, Kefford R, Sober A, Halpern A, Garbe C, Scolyer R. Springer, Cham: Switzerland, 1-34, 2019. PMID: 978-3-319-46029-1.

#### Books (edited and written)

N/A

#### Letters to the Editor

N/A

#### Manuals, Teaching Aids, Other Teaching Publications

N/A

#### Other Publications

N/A

#### EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Senior Editor for Melanoma, Clinical Cancer Research, 2017-present

**Member of Editorial Review Board**

Board Member, Biochemical Pharmacology, 2010

Board Member, Precision Oncology, 2013

**Journal Reviewer**

Reviewer, British Journal of Dermatology, 2009

Reviewer, Disease Models & Mechanisms, 2009

Reviewer, International Journal of Experimental Pathology, 2009

Reviewer, Cancers, 2010

Reviewer, Integrative Biology, 2010

Reviewer, Journal of Cancer Research, 2010

Reviewer, Recent Patents on Anti-Cancer Drug Discovery, 2010

Reviewer, Cancer Research, 2010-present

Reviewer, Clinical Cancer Research, 2010-present

Reviewer, Pigmented Cell and Melanoma Research, 2010-present

Reviewer, PLOSone, 2010-present

Reviewer, Biomarkers in Medicine, 2011

Reviewer, Cellular and Molecular Life Sciences, 2011

Reviewer, Proceedings of the National Academy of Science (PNAS), 2011

Reviewer, American Journal of Clinical Dermatology, 2012

Reviewer, Expert Review of Anticancer Therapy, 2012

Reviewer, Journal of Investigative Dermatology, 2012

Reviewer, IUBMB Life, 2013

Reviewer, Journal of the National Comprehensive Cancer Network, 2013

Reviewer, Cancer Discovery, 2015

Reviewer, Cancer Cell, 2017-present

**Other Editorial and Review Activities**

Guest Editor, The Cancer Journal, 2012

**TEACHING**

**Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center**

**Formal Teaching**

**Courses Taught**

Instructor, Clinical Principles of Cancer Metastasis, Course Number: GS041012, Course Hours: 1.5  
10/2010

Lecturer, Fellow Didactic Lecture - Development of rational targeted therapy approaches for melanoma  
11/2010

Lecturer, Fellow Didactic Lecture - Development of rational targeted therapy approaches for melanoma  
4/2011

Instructor, Principles of Therapeutics, Course Number: GS04-1103, Course Hours: 1  
5/2011



Lecturer, Proteomic Analysis of Cancer/Analysis of Patient Derived Specimens, Course Number: GS210121  
6/2011

Lecturer, Fellow Didactic Lecture - Development of rational targeted therapy approaches for melanoma  
8/2011

Lecturer, Fellow Didactic Lecture - Development of rational targeted therapy approaches for melanoma  
10/2011

Instructor, Resources and Methods for Analysis of Patient-Derived Samples, Course Number: GS211121, Course Hours: 1  
Summer, 2011

Lecturer, The Development of Rational Therapeutic Strategies for Melanoma, GME Core Curriculum Lecture Series  
2/2012

Lecturer, Principles of therapeutics - Targeted Therapy, University of Texas - Graduate School of Biomedical Sciences, Course Number: GS04-1103  
4/2012

Lecturer, Proteomic Analysis of Cancer/Analysis of Patient Derived Specimens, Course Number: GS210121  
6/2012

Lecturer, MD Anderson Hematology/Oncology Board Review Course, "Melanoma 2012"  
9/2012

Lecturer, Principles of Therapeutics - Targeted Therapy, Course Number: GS04-1103  
4/2013

Lecturer, The Development of Rational Therapeutic Strategies of Melanoma, GME Core Curriculum Lecture Series  
5/2013

Lecturer, Identification and Targeting of Oncogenic Drivers in Melanoma  
6/2013

Lecturer, Proteomic Analysis by Antibodies/Analysis of Patient-Driven Samples, Course Number: GS21 0121  
6/2013

Lecturer, The Development of Rational Therapeutic Strategies of Melanoma, GME Core Curriculum Lecture Series  
8/2013

Instructor, Introduction to Research Activities: Melanoma Molecular Biology and Therapy  
9/2014

Lecturer, MD Anderson Cancer Center Oncology  
9/2014

Lecturer, MD Anderson Hematology/Oncology Board Review Course, "Melanoma 2014"  
9/2014

Instructor, Targeted Therapy for Melanoma: Lessons Learned, Current Challenges, and Future Directions  
9/2014

Lecturer, Art and Science of the Evolving Melanoma Landscape, Course Number: D112515  
Fall, 10/2014

Lecturer, Mechanisms in Cancer Therapeutics, "Targeting BRAF", Course Hours: 1  
11/2014

Lecturer, A new era in the treatment of Melanoma  
11/2014

Lecturer, Mechanisms in Cancer Therapeutics, Course Number: GS04 1213  
11/2014

Lecturer, Principles of Therapeutics: Targeted Therapy  
5/2015

Lecturer, Proteomic Analysis by Antibodies  
Summer, 7/2015

Lecturer, MD Anderson Hematology/Oncology Board Review Course, "Melanoma 2015"  
9/2015

Lecturer, Principles of Therapeutics: Targeted Therapy  
4/2016

Lecturer, Principles of Therapeutics, Course Number: GS04 1103  
4/2017

Lecturer, Melanoma Update Hematology/Oncology Fellowship Program  
5/2017

Lecturer, Principles of Therapeutics: Targeted Therapy  
4/2018

**Training Programs**

Initiator, T32 Training in Research Seminar Series, MD Anderson Cancer Center  
2013-present

**Other Formal Teaching**

N/A

**Supervisory Teaching**

**Committees**

**Advisory Committees**

Rodabe Amaria, MD, 5/2015

Committee Member, GSBS, Iman Sahnoune, Ph.D., 9/2018-present

Amy Jones, Fellow

Asrin Jaiswal

Callie Kwartler, GSBS

Chandrani Chattopadhyay, PhD

Chantale Bernatchez, PhD

Dong Yang, Fellow

Geoffrey Grandjean, GSBS

Grant Fischer, MD/PhD Program

Isabella Glitza, MD Ph.D

Jahan Khalili, GSBS

James Link, Fellow

Jennifer McQuade, Fellow

Kauser Ahmed, GSBS

Keila Torres, Fellow

Meredith McKean, Fellow  
Pavlos Msouel, Fellow  
Richard Joseph, Fellow  
Robert Sloane Szczepaniak  
Sapna Patel, Fellow  
Vashisht Yennu Nanda, PhD  
Yan Yang, GSBS  
Yared Hailemichael, PhD

**Supervisory Committees**

Geoffery Grandjean, PhD  
Grant Fischer, MD/PhD  
Jessica Ann Hernandez, GSBS  
Matthew Campbell, GSBS

**Examining Committees**

Joshua Rother, GSBS  
Kausar Ahmed, GSBS  
Nathan Ihle, GSBS  
Robert Sloane Szczepaniak, GSBS

**Direct Supervision**

**Undergraduate and Allied Health Students**

Pilar O'neal, 6/2018-8/2018

**Medical Students**

N/A

**Graduate Students**

Antony Ansu, 10/2010-6/2011  
Krishna C. Vadlamudi, 10/2010-6/2011  
Pushan Dasgupta, 6/2011-8/2012  
Lalit Patel, 6/2012-7/2012  
Grant Fischer, 9/2015-present  
Renato Guerrieri, 2019-present

**Postdoctoral Research Fellows**

Guo Chen, 10/2010-12/2015

**Clinical Residents and Fellows**

Scott E Woodman, MD, PhD, MDACC, 2008-2010  
Richard W. Joseph, MD, MDACC, 2009-2011  
John A Jakob, MD, MDACC, 2010-2011  
Jeffrey Yorio, 2012-2013  
Amanda Bucheit, MD, MDACC, 2012-2014  
Jan Kemnade, MD, BCM, 2014-2017  
Jennifer McQuade, MD, 2014-2018  
Amy Jones, 2017-2019

**Other Supervisory Teaching**

Vashisht Gopal Yennu Nanda, Instructor, Direct Supervisor, 8/2008-12/2011

**Teaching Outside Current Institution**

**Formal Teaching**

**Courses Taught**

Lecturer, BCM Hem/Onc Fellowship Program, Baylor College of Medicine

5/2011

Lecturer, Integrated Analysis of Signaling Pathways in Melanoma, UT-Houston Medical School

8/2011

Lecturer, BCM Hem/Onc Fellowship Program, Baylor College of Medicine

10/2012

Lecturer, Translational Cancer Biology Course: Melanoma, Baylor College of Medicine

3/2013

Lecturer, BCM Hem/Onc Fellowship Program, Baylor College of Medicine

9/2013

Lecturer, Current and Emerging Treatment Strategies for Advanced Melanoma, Houston Northwest Medical Center, Course Hours: 1

10/2014

Lecturer, BCM Hem/Onc Fellowship Program, Baylor College of Medicine

11/2014

Lecture, Innovations in Cancer Treatment and Prevention, Glasscock School of Continuing Studies, Rice University

Fall, 10/2016

Lecturer, BCM Hem/Onc Fellowship Program: Melanoma, Baylor College of Medicine

6/2017

**Training Programs**

N/A

**Other Formal Teaching**

N/A

**Supervisory Teaching**

**Committees**

**Advisory Committees**

UT Southwestern, Xiaolei Shi, 2015-present

**Supervisory Committees**

UT Southwestern, Xiaolei Shi, 2015-present

**Examining Committees**

Baylor College of Medicine, Hengyu Lu, 6/2013

UT Southwestern, Xiaolei Shi, 2015-present

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

N/A

**Graduate Students**

University of Sao Paulo, Cristiano Goncalves Pereira, 3/2013-2013

**Postdoctoral Research Fellows**

N/A

**Clinical Residents and Fellows**

N/A

**Other Supervisory Teaching**

N/A

**CONFERENCES AND SYMPOSIA**

**Organization of Conferences/Symposia (Include chairing session)**

103rd Annual AACR Meeting, American Association of Cancer Research, Chicago, IL, Chair - Melanoma: Moving beyond BRAF, 3/2012

Global Academic Programs 2013 - Moon Shots: Connect for Global Networking, MD Anderson Cancer Center, Houston, TX, Co-Chair - Striving for Cures in Melanoma Session, 4/2013

MDACC and AIM Melanoma Patient Symposium, Houston, TX, Co-Organizer, 1/2015

Melanoma Research Foundation Brain Metastasis, Philadelphia, PA, Co-Organizer, 12/2015

Medical Education Program on Melanoma Management, MD Anderson Cancer Center, Houston, TX, Co-Organizer, 5/2016

MDACC Melanoma CME Conference, MD Anderson Cancer Center, Houston, TX, Co-Organizer, 9/2016

Medical Education Program on Melanoma Management, MD Anderson Cancer Center, Houston, TX, Organizer, 11/2016

SMR 2016 Annual Meeting, Boston, MA, Planning Committee, 11/2016

SMR 2016 Annual Meeting, Oncogenic Signaling Pathways in Immunotherapy Resistance, Boston, MA, Chair, 11/2016

SMR Neoadjuvant Workshop, SMR 2016 Annual Meeting, Boston, MA, Co-Organizer, 11/2016

MDACC and MRF Melanoma Patient Symposium, MD Anderson Cancer Center, Austin, TX, Organizer, 5/2017

MDACC Melanoma CME Conference, Houston, TX, Co-Organizer, 9/2017

Melanoma Research Foundation Brain Metastasis Research Summit, Tampa, FL, Planning Committee, 2/2018

MDACC Melanoma CME Conference, MD Anderson Cancer Center, Houston, TX, Co-Organizer, 9/2018

2019 AACR Special Conference on Melanoma: from Biology to Target, Houston, TX, Chair Session, 1/2019

2019 Global Academic Programs Conference, Houston, TX, Chair, 5/2019

**Presentations at National or International Conferences**

**Invited**

**Davies MA.** Biological responses to MMAC/PTEN reintroduction in various human cancers, 14th Annual M.D. /PhD. Conference, Aspen, CO, 1999

**Davies MA.** Different biological responses to MMAC/PTEN reintroduction in various human cancers, Keystone Symposium: Specificity in Signal Transduction, Keystone, CO, 1999

**Davies MA.** The Biology of AKT in Melanoma, 15th SPORE Investigators' Workshop, Baltimore, MD, 7/10/2007

**Davies MA.** Assessment of AKT activation in Melanoma: Relation to Mutations, Anatomic Sites, and Clinical Outcomes, SPORE in Skin Cancer Spring Talk Series, Wistar Institute, Philadelphia, PA, 5/8/2009

**Davies MA.** Reverse phase protein array (RPPA) analysis to characterize protein signaling networks in melanoma, National Melanoma SPORE Summer Workshop, Houston, TX, 6/2/2010

**Davies MA.** Targeted therapy in melanoma-lessons learned and future directions, MD Anderson Cancer Center, 6th Annual Symposium, New York, NY, 8/16/2010

**Davies MA.** Mechanisms of Resistance to AZD6244 in BRAF-Mutant Melanoma, Tumor metabolism and P13K signalling symposium, Astrazeneca, Manchester, England, United Kingdom, 9/17/2010

**Davies MA.** Emerging challenges for personalized cancer therapy: insights from studies of the PI3K-AKT pathway, Symposia on Cancer Research 2010, Houston, TX, 10/8/2010

**Davies MA.** Targeted therapy for Melanoma - Where do we go from here?, Southwest Oncology Group Fall 2010 Group Meeting, Southwest Oncology Group (SWOG), Chicago, IL, 10/22/2010

**Davies MA.** Personalized Targeted Therapy for Cancer, Joint Symposium on Cancer Research, Barretos Cancer Hospital, Barretos, Brazil, 11/2010

**Davies MA.** Perspectives on Systemic Therapy for Melanoma, Joint Symposium on Cancer Research, Barretos Cancer Hospital, Barretos, Brazil, 11/2010

**Davies MA.** The Molecular Biology of Melanoma, Joint Symposium on Cancer Research, Barretos Cancer Hospital, Barretos, Brazil, 11/2010

**Davies MA.** Systemic Therapy for Melanoma, Current Concepts in Head and Neck Surgery, UT MD Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center and University of Toronto, Houston, TX, 11/20/2010

**Davies MA.** B-RAFi GSK2118346 Presurgical Evaluation in Patients with Operable Brain Metastasis and Proven V600E Mutations (Protocol iMWG 02), International Melanoma Working Group (IMWG), AIM at Melanoma, Naples, Italy, Italy, 12/4/2010

**Davies MA.** The Molecular Biology and Therapy of Melanoma Brain Metastases: A Phase II Trial of GSK2118436 for BRAF-Mutant melanoma Patients with Brain Metastases (BRF113929), Melanoma Medical Oncology Grand Rounds, UT MD Anderson Cancer Center, Houston, TX, 3/7/2011

**Davies MA.** Integrated Analysis of Signaling Pathways in Melanoma, 102nd AACR Annual Meeting, American Association of Cancer Research, Orlando, FL, 4/2/2011

**Davies MA.** Novel Targets in Melanoma, 102nd AACR Annual Meeting, American Association for Cancer Research, Orlando, FL, 4/2/2011

**Davies MA.** BRAF Inhibition in Melanoma Brain Metastases, International Melanoma Working Group Symposium, Barcelona, Spain, 4/11/2011

**Davies MA.** A View to the Future: The Treatment of Melanoma, 2011, Northern Trust Ft. Lauderdale, UT MD Anderson Cancer Center, Ft. Lauderdale, FL, 5/12/2011

**Davies MA.** A View to the Future-Personalized Therapy for Melanoma, Melanoma Research Foundation Northwest Melanoma Symposium, Seattle, WA, 5/13/2011

**Davies MA.** Beyond BRAF: Additional molecular targets in Melanoma, Advanced Melanoma: Biology and Treatment, Boston, MA, 6/29/2011

**Davies MA.** Evaluation of BRAF/NRAS Mutations and PTEN expression in advanced Melanoma, Melanoma SPORE Summer Workshop, Boston, MA, 6/30/2011

**Davies MA.** Beyond BRAF: Additional molecular targets in Melanoma, NCI Translational Science Meeting, Washington, DC, 7/29/2011

**Davies MA.** Regulation and Function of the PI3K Pathway in Melanoma, IPCC 2011: Bridging Clinical Medicine and Science, Bordeaux, France, 9/23/2011

**Davies MA.** A view to the future: Personalized Therapy for Melanoma, U.T. MD Anderson Cancer Center, 5th Annual Cullen Trust for Higher Education Translational Research Symposium, Houston, TX, 1/13/2012

**Davies MA,** Guo C, Liu DD, Malke J, Gershenwald JE, Lazar AJ. Molecular and Clinical Correlates of PTEN Expression in Melanoma, 103rd Annual AACR Meeting: Education Session, American Association of Cancer Research, Chicago, IL, 4/1/2012

**Davies MA.** The MAP Kinase Pathway in Melanoma: A Primer for Clinicians, University of Cincinnati, Medical Learning Institute, Inc., and Center of Excellence Media, LLC in collaboration with Core Principle Solutions, LLC, World Cutaneous Malignancies Congress, 2012, Montreal, CA, Canada, 4/21/2012

**Davies MA.** Targeted Therapy for Melanoma, 2012, MDACC Medical Oncology and Hematology Symposium, UT MD Anderson Cancer Center, Houston, TX, 10/19/2012

**Davies, MA.** Identifying therapeutic targets for melanoma brain metastases, Melanoma Research Alliance, 5th Annual Scientific Retreat, Washington, DC, 2/27/2013

**Davies MA.** Molecular Testing in Melanoma, 2013, MD Anderson Cancer Center, Global Academic Programs Conference 2013 - Moon Shots: Connect for Global Networking, Houston, TX, 4/3/2013

**Davies MA.** Melanoma 2013: New Strategies and Treatments, The 24th Annual Mary Mulready Sullivan Oncology Symposium, Hartford Hospital Helen & Harry Gray Cancer Center, Hartford, CT, 5/15/2013

**Davies MA.** Scientific Discussant, American Society of Clinical Oncology, Chicago, IL, 6/2013

**Davies MA.** Molecular Pathology of Cutaneous Melanoma: A Basic Science Perspective, 2013 World Cutaneous Malignancies Congress, San Diego, CA, 7/26/2013

**Davies MA.** Recurrent Mutations in Melanoma, Imedex, Melanoma Perspectives XVII, Baltimore, MD, 9/1/2013

**Davies MA.** Targeting Melanoma Brain Metastases, AIM at Melanoma Foundation, International Melanoma Working Group, Chantilly, VA, 9/1/2013

**Davies MA.** Systemic Therapy for Melanoma, 2013, 2013 SOLCA National Congress of Oncology, Quito, Ecuador, 11/12/2013

**Davies MA.** Debate: Should Patients with BRAFmut metastatic melanoma get a BRAF+/- MEK inhibitor first-line? Response "Yes," 1st Annual Summit on Practical and Emerging Trends, Dallas, TX, 5/2014

**Davies MA.** Debate: Should Patients with BRAFmut metastatic melanoma get a BRAF+/- MEK inhibitor first-line? Response "Yes," 1st Annual Summit on Practical and Emerging Trends, Oncology Meeting Innovations, Dallas, TX, 5/2014

**Davies MA.** Intersection of PI3K-AKT Pathway Signaling, Metabolism and Therapeutic Resistance, AACR Annual Meeting, San Diego, CA, 5/2014

**Davies MA.** NRAS and CDK targeted therapy in melanoma, Oncology Meeting Innovations, Dallas, TX, 5/2014

**Davies MA.** Overview of Metastatic Melanoma, including Staging and Diagnosing Current Standing of Care, CancerCare Teleconference, Emerging Treatments for Metastatic Melanoma, 5/9/2014

**Davies MA.** Molecular Basis for Combinatorial Strategies in Melanoma, ASCO Annual Meeting, 6/2014

**Davies MA.** Melanoma- Onward and Upward, ASCO 2014 Highlights, Milwaukee, WI, 7/2014

**Davies MA.** Molecular Biology and Testing in the Oncology Clinic, College of American Pathologists, Chicago, IL, 9/2014

**Davies MA.** Melanoma signaling pathways: clinical outcomes, therapeutic resistance, and metabolism, Moffitt Cancer Center, Tampa, FL, 12/2014

**Davies MA.** The multi-faceted roles of the PI3K-AKT pathway in melanoma, Melanoma Bridge 2014, Naples, Italy, 12/2014

**Davies MA.** Clinical and Therapeutic Significance of the PI3K-AKT Pathway in Melanoma, Canadian Melanoma Conference, Vancouver, British Columbia, 2/2015

**Davies MA.** Opportunities and needs for molecular imaging in melanoma, American Association for Melanoma Research, San Diego, CA, 2/2015

**Davies MA.** Targeting the PI3K-AKT Pathway in Melanoma, AIM at Melanoma, IMWG, Krakow, Poland, 3/2015

**Davies MA.** Emerging Treatments for Metastatic Melanoma, Cancer Care Webinar, New York, NY, 5/2015

**Davies MA.** Target BRAF V600: Response & Resistance to BRAF/MEK Inhibition, 2015 ASCO Annual Meeting Illumination & Innovation Conference, Chicago, IL, 5/2015

**Davies MA.** The Rapidly Evolving Landscapes of Systemic Therapies for Advanced Melanoma: Achievements, Challenges, and Opportunities, Melanoma: From Screening to Revolutionary New Therapies, Mount Laurel, NJ, 6/2015

**Davies MA.** Molecular Biology and Therapy of Melanoma CNS Metastasis, UTMB Health, 4th UTMB Brain Symposium, Galveston, TX, 9/2015

**Davies MA.** Molecular Profiling in Melanoma, 2015, EPIC Melanoma in 2015 and Beyond, An Expert Panel Discussion, Cleveland, OH, 9/2015

**Davies MA.** Molecular Biology and Testing in the Oncology Clinic, College of American Pathologists, CAP '15 Advancing Diagnostic Medicine, Nashville, TN, 10/2015

**Davies MA.** Translating the Molecular Biology of Melanoma in the Clinic, Fall 2015 Southwest Oncology Group SWOG Meeting, Chicago, IL, 10/2015

**Davies MA.** Integrated Risk Modeling of Primaries, International Melanoma Working Group, AIM At Melanoma Foundation, Marseille, Italy, 11/1/2015

**Davies MA.** The Role of the PI3K-AKT Pathway in Melanoma Brain Metastasis, Society for Melanoma Research, San Francisco, CA, 11/18/2015

**Davies MA.** The role and therapeutic potential of Oxidative Phosphorylation in melanoma, Melanoma SPORE Annual Meeting, Philadelphia, PA, 12/2015

**Davies MA.** Immunologic and metabolic consequences of the PI3K-AKT pathway in melanoma, Melanoma Bridge 2015, Naples, Italy, 12/2/2015

**Davies MA.** Role of the PI3K-AKT pathway in melanoma brain metastasis., Melanoma Research Foundation Brain Metastasis Summit, Philadelphia, PA, 12/8/2015

**Davies MA.** The role and therapeutic potential of Oxidative Phosphorylation in Melanoma, Melanoma SPORE Annual Meeting, Philadelphia, PA, 12/8/2015

**Davies MA.** Decoding the disease: unravelling the mutations and pathways driving melanoma, Novartis Melanoma Lung Conference, Los Angeles, CA, 2/2016

**Davies MA.** Now It's Personal: Individualizing Treatments in Melanoma, PRISM 2016, Amsterdam, Netherlands, 4/2016

**Davies MA.** Onward and Upward: Future Landscape in Melanoma, PRISM 2016, Amsterdam, Netherlands, 4/2016

**Davies MA.** Molecular Targets and Therapy, ASCO Annual Meeting '16, Chicago, IL, 6/2016

**Davies MA.** New-Paradigms-The Rapidly Evolving Landscape of Melanoma, OhioHealth, Dublin, OH, 6/11/2016



**Davies MA.** Immunotherapy Trials and Translational Research for LMD, 2016 Inter-SPORE Retreat, Pittsburgh, PA, 7/2016

**Davies MA.** Melanoma brain metastases-Insights into the Molecular Biology and Therapeutic Perspectives, 26th German Skin Cancer Congress, Dresden, Germany, 9/2016

**Davies MA.** Can neoadjuvant targeted therapy beat standard of care therapy?, SMR 2016 Annual Meeting, Boston, MA, 11/2016

**Davies MA.** COMBI-MB: a phase 2 study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant (mut) melanoma brain metastases (MBM), 2017 ASCO Annual Meeting, Chicago, IL, 6/2017

**Davies MA.** Integrating immune and targeted therapy in melanoma, Karolinska Institutet Workshop, Karolinska Institutet, Stockholm, Sweden, 9/24/2017

**Davies MA.** Integration of Immunotherapy and Oncogenic Signaling Pathways in Cancer, Society for Immunotherapy of Cancer, District of Columbia, WA, 11/2017

**Davies MA.** The Role of Metabolism in Therapy and Brain Metastasis in Melanoma, International Melanoma Working Group, Florence, Italy, 11/4/2017

**Davies MA.** Integration of Immunotherapy and Oncogenic Signaling Pathways in Cancer, Society for Immunotherapy of Cancer Annual Meeting, Oxen Hill, MD, 11/11/2017

**Davies MA.** BIG NEWS: The Obesity Paradox of Melanoma, Melanoma Bridge 2017, Naples, Italy, 12/2017

Front-Line Therapy for Disseminated Melanoma: Current Standards and Future Directions, 17th Annual Oncology Update: Advances and Controversies, Breckenridge, CO, 1/21/2018

**Davies MA.** Genetic and Clinical Variance in Response to Melanoma Treatment, 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies, New York City, NY, 2/10/2018

**Davies MA.** Integrated Interrogation of Oncogenic Signaling Pathways, Immunology, and Heterogeneity in Cancer, 2018 Advances in Genome Biology and Technology, Orlando, FL, 2/13/2018

**Davies MA.** Melanoma Brain Metastases: Targeted Therapy Clinical Trials, Melanoma Research Foundation BrainMetastasis Research Summit, Tampa, FL, 2/18/2018

**Davies MA.** Molecular Biology of Melanoma Brain Metastases, Melanoma Research Foundation Brain Metastasis Research Summit, Tampa, FL, 2/18/2018

**Davies MA.** Targeting BRAF mutant brain metastasis, Melanoma Research Alliance 10th Annual Scientific Retreat, Washington, DC, 3/1/2018

**Davies MA.** Targeting BRAF-mutant melanoma brain metastasis, 10th Annual Melanoma Research Alliance Research Meeting, Washington, DC, 3/1/2018

**Davies MA.** Brain Metastases: Intrathecal Therapy and Targeted Therapy, International Melanoma Working Group, Edinburgh, Scotland, 3/24/2018

**Davies MA.** Breakthroughs in systemic therapy for brain metastases, Australasian Melanoma Conference 2018, Melbourne, Australia, 10/2018

**Davies MA.** Breakthroughs in systemic therapy for brain metastases, 2018 Australasia Melanoma Conference, Melbourne, Australia, 10/6/2018

**Davies MA.** Emerging strategies for combination immunotherapy in melanoma, Melanoma Bridge 2018, Naples, Italy, 12/2018

**Davies MA.** Distinct immune and molecular features of melanoma brain metastases, AACR Special Conference on Melanoma: From Biology to Target, Houston, TX, 1/16/2019

**Davies MA.** Front-Line Therapy for Disseminated Melanoma: Current Standards and Future Directions, 17th Annual Oncology Update: Advances and Controversies, Breckenridge, CO, 1/21/2019

**Davies MA.** New Paradigm in the Treatment of Melanoma Brain Metastases: Are we Finally Making Progress?, 17th Annual Oncology Update: Advances and Controversies, Breckenridge, CO, 1/21/2019

**Davies MA.** Will Targeted Therapy Replace Whole Brain Radiation (WBXRT) in Melanoma Brain Metastases?, 2019 ASCO Annual Meeting, Chicago, IL, 6/4/2019

**Davies MA.** Update on Melanoma Brain Metastasis Initiatives, Melanoma SPORE, Philadelphia, PA, 7/16/2019

#### **Other, Including Scientific Exhibitions**

**Davies MA.** Functional Proteomics for Development of Individualized Cancer Therapy, Beckman Coulter Symposium 2007, 8/2007

**Davies MA.** Debate: Should Patients with BRAFmut metastatic melanoma get a BRAF+/- MEK inhibitor first-line? Response "Yes,, Oncology Meeting Innovations, 1st Annual Summit on Practical and Emerging Trends, Dallas, TX, 5/2014

**Davies MA.** CNS Metastases: The Role of Systemic Therapy, MD Anderson Cancer Center, MD Anderson CME Conference, Houston, TX, 9/2018

**Davies MA.** Current Treatments and Investigations for CNS Metastases, FDA Brain Metastasis Workshop, Bethesda, MD, 3/22/2019

#### **Seminar Invitations from Other Institutions**

Assessing Protein Networks by Reverse Phase Protein Arrays, UTHSC Scleroderma and Fibrosing Disorder Research Seminar, University of Texas at Houston Medical School, Houston, TX, 12/13/2007

Assessment of AKT activation in Melanoma: Relation to Mutations, anatomic sites, and clinical outcomes, Wistar Institute, Philadelphia, PA, 5/2009

The Development of Rational Targeted Therapy for Melanoma, Multidisciplinary Oncology Conference, ProHealth Care Regional Cancer Center, Waukesha, WI, 8/24/2009

The development of rational targeted therapy for melanoma, Internal Medicine Grand Rounds, University of Texas at Houston Medical School, Houston, TX, 8/25/2009

Integrated Clinical and Molecular Analysis of the PI3K-AKT Pathway in Melanoma, Interdisciplinary Melanoma Cooperative Program, NYU Langone Medical Center, New York, NY, 1/28/2010

The Role of the PI3K-AKT Pathway in Melanoma, Huntsman Cancer Institute, Salt Lake City, UT, 3/19/2012

The role of the PI3K-AKT pathway in melanoma, MGH Melanoma Seminar Series, Massachusetts General Hospital, Boston, MA, 5/1/2012

The role of the PI3K-AKT Pathway in Melanoma, Joint Research Seminar Series, Jefferson Kimmel Cancer Center, Philadelphia, PA, 5/24/2012

The Role of the PI3K-AKT Pathway in Melanoma, Clinical Oncology Grand Rounds, University of Pittsburgh Medical Center, Pittsburgh, PA, 3/12/2013

The Role of the PI3K-AKT Pathway in Melanoma, Vanderbilt-Ingram Cancer Center, Nashville, TN, 6/20/2013

Molecular Biology and Therapy of Melanoma Brain Metastases, Memorial Sloan Kettering Cancer Center, New York, NY, 11/15/2013

Proteomic Analysis of the PI35-AKT Signaling Pathway in Melanoma, Baylor College of Medicine / MD Anderson Cancer Center Joint Symposium, Houston, TX, 1/10/2014

Systemic Therapy for Melanoma, 2014: How did we get here and where are we going?, ASLMC Medicine Grand Rounds, Aurora Health Care, Milwaukee, WI, 1/30/2014

The role of the PI3K-AKT pathway in melanoma, Sanford Burnham Medical Research Institute, San Diego, CA, 2/18/2014

The Multi-Faceted Roles of the PI3K-AKT Pathway in the Pathogenesis and Therapeutic Resistance of Melanoma, Wistar Institute, Philadelphia, PA, 1/16/2015

"The PI3K-AKT Pathway in Melanoma Pathogenesis, Progression, and Resistance," 26th German Skin Cancer Conference, Essen, Germany, 9/2016

New Paradigms-The Rapidly Evolving Understanding and Management of Melanoma, Tifton Regional Medical Center, Tifton, GA, 10/2016

The Role of the PI3K-AKT Pathway in Brain Metastasis and Therapeutic Resistance in Melanoma, University of Georgia, Athens, GA, 10/2016

The PI3K-AKT Pathway in Melanom-Metastasis, Metabolism, and Resistance, Divisional Grand Rounds, Columbia University Medical Center, Division of Hematology/Oncology, New York, NY, 1/2017

New Paradigms and New Questions: The Rapidly Evolving Landscape and Management of Melanoma, UT Southwestern Medical Center, Dallas, TX, 7/3/2017

"BIG News! The role of obesity in melanoma," Wistar Institute, Philadelphia, PA, 1/10/2018

Unraveling the role of metabolism in melanoma, UPMC Hillman Cancer Center, Pittsburgh, PA, 2/13/2019

Immunotherapy for Stage IV Melanoma, 2nd Annual Melanoma Symposium, Banner Healthcare, Phoenix, AZ, 2/16/2019

#### **Lectureships and Visiting Professorships**

N/A

#### **Other Presentations at State and Local Conferences**

**Davies MA.** Studies of the tumor suppressor MMAC/PTEN in human glioblastoma multiforme and prostate cancer cells, Grand Rounds, MD Anderson Cancer Center, Houston, TX, 2000

**Davies MA.** The functional role of the tumor suppressor MMAC/PTEN in glioblastoma multiforme and prostate cancer cells, Cancer Metastasis Research Seminar Series, MD Anderson Cancer Center, Houston, TX, 2000

**Davies MA.** How to Analyze a High- Throughput Screen, A Workshop on High Throughput/ High Content Screening & its application to Targeted-based Drug Discovery Research, John S. Dunn GCC Consortium for Chemical Genomics, Houston, TX, 11/8/2007

**Davies MA.** How to find a balance between lab work, personal life, and academics through the MD/PhD program, residency, fellowship, and beyond, MD/PhD Career Development Workshop, Baylor College of Medicine, Houston, TX, 1/12/2008

**Davies MA.** The Development of Rational Targeted Therapy for Advanced Melanoma, Experimental Therapeutics Departmental Seminar, MD Anderson Cancer Center, Houston, TX, 1/23/2008

**Davies MA.** Development of Rational Targeted Therapy Approaches for Melanoma:Project Update, Melanoma Medical Oncology Weekly Lab Meeting, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX, 5/19/2008

**Davies MA.** Update on Melanoma: New Molecular Insights and Therapies, Advances in Oncology Institutional Grand Rounds, MD Anderson Cancer Center, Special Medical Education Programs, Houston, TX, 8/1/2008

**Davies MA.** Integrated Analysis of Mutations and Activation of the PI3K-AKT Pathway in Cancer, Grand Rounds, MD Anderson Cancer Center, Houston, TX, 7/31/2009

- Davies MA.** Developing Rational Targeted Therapy Approaches for Melanoma, Internal Medicine Grand Rounds, UT-Medical School at Houston, Houston, TX, 8/25/2009
- Davies MA.** Evaluation of targeted therapies for BRAF-mutant melanoma, Research Meeting, MD Anderson Cancer Center, Endocrine Neoplasia & Hormonal Disorders, Houston, TX, 8/28/2009
- Davies MA.** A view to the future- the development of targeted therapy for melanoma, Science to Survivorship Symposium, MD Anderson Cancer Center, Houston, TX, 9/26/2009
- Davies MA.** A new paradigm- personalized therapy for melanoma, MD Anderson Cancer Center, Physicians Network, Houston, TX, 5/26/2010
- Davies MA.** Overcoming Resistance to MAPK Pathway Inhibitors in Melanoma, Department of Experimental Therapeutics Center for Targeted Therapy Seminar Series, MD Anderson Cancer Center, Houston, TX, 5/26/2010
- Davies MA.** Regulation and Function of the P13K/AKT Pathway in Melanoma, Clinical Trials Faculty Meeting, MD Anderson Cancer Center, Investigational Cancer Therapeutics, Houston, TX, 1/5/2011
- Davies MA, Chair.** A New Era for Melanoma: Targeted Therapy for BRAF, Advances in Oncology Institutional Grand Rounds, MD Anderson Cancer Center, Houston, TX, 6/10/2011
- Davies MA.** Molecular biology and therapy of melanoma brain metastases, Patient Access Inservice, MD Anderson Cancer Center, Patient Access, Houston, TX, 6/10/2011
- Davies MA.** Integrated analysis of signaling pathways in Melanoma, The University of Texas Houston Medical School Internal Medicine Research Seminar Series, UT-Houston Medical School, Houston, TX, 8/4/2011
- Davies MA.** Targeted Therapy for Melanoma, MD Anderson Symposium: Advances that Change Physician Practice, MD Anderson Cancer Center, Houston, TX, 10/22/2011
- Davies MA.** A view to the future: Personalized therapy for cancer, CCSG and Cancer Prevention Workshop, MD Anderson Cancer Center, Cancer Prevention, Houston, TX, 11/5/2011
- Davies MA.** Resistance to MAPK Pathway Inhibition in Melanoma, Melanoma and Skin Cancer Research Program Seminar Series, Melanoma SPORE, MD Anderson Cancer Center, Melanoma, Houston, TX, 11/17/2011
- Davies MA.** The Development of Rational Targeted Therapy for Melanoma, MD Anderson Cancer Center, Radiation Oncology, Houston, TX, 12/1/2011
- Davies MA.** Molecular Biology of Melanoma: Prognostic and Predictive Factors, MDACC Diagnostics in Molecular Pathology Seminar Series, MD Anderson Cancer Center, Houston, TX, 8/20/2012
- Davies MA.** The role of the PI3K-AKT pathway in Melanoma, IACS Experimental Therapeutics Seminar Series, MD Anderson Cancer Center, Genomic Medicine, Houston, TX, 8/22/2012
- Davies MA.** The role of the PI3K-AKT pathway in Melanoma, Sarcoma Research Center Seminar, MD Anderson Cancer Center, Houston, TX, 9/21/2012
- Davies MA.** The role of the PI3K-AKT pathway in Melanoma, Melanoma and Skin Cancer Research Seminar Program, MD Anderson Cancer Center, Houston, TX, 10/18/2012
- Davies MA, Cain S.** Protocol 2012-0470 "Phase I/II study of SAR260301 (P13K-beta inhibitor) as monotherapy in patients with advanced solid tumors, and in combination with vemurafenib in patients with metastatic BRAF-mutant melanoma" Details & Rationale, MD Anderson Cancer Center, Houston, TX, 12/3/2012
- Davies MA.** From the Bench to the Bedside- Targeting BRAF in Melanoma, MDACC Hematology Oncology Fellowship Program, MD Anderson Cancer Center, Houston, TX, 12/4/2012
- Davies MA.** Best of ASCO 2013 Annual Meeting: Melanoma, Melanoma Medical Oncology Grand Rounds, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX, 7/8/2013

**Davies MA.** Clinical Next-Generation Sequencing in Advanced Melanoma: The MD Anderson Experience, Symposia on Cancer Research 2013, "Genomic Medicine," , Houston, TX, 10/1/2013

**Davies MA.** Integrated analysis and targeting of oncogenic drivers and the anti-tumor immune response to improve outcomes and personalize therapy across the melanoma continuum, Institutional Grand Rounds, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2/21/2014

**Davies, MA.** Melanoma Brain Metastases: Molecular Characterization and Treatment, Training in Brain Tumor Research Seminars, UT MD Anderson Cancer Center, Houston, TX, 11/10/2014

**Davies MA.** Recent Advances in the treatment of Option for Metastatic Melanoma, Emerging Treatment Strategies in the Treatment of Cancer for Practicing and Healthcare Professionals, A. Webb Roberts Center for CME of Baylor Health Care Systems, CancerNet, and American Health Resource, Inc., CancerNet, LLC, Houston, TX, 8/2015

**Davies MA.** Targeted Therapy for Melanoma: A Personalized Approach, AIM Patient Symposium, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX, 8/15/2015

**Davies MA.** Optimizing Targeted Therapy for Melanoma, The Division of Cancer Medicine Grand Rounds, MD Anderson Cancer Center, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, TX, 8/18/2015

**Davies MA.** Unraveling and Translating the Molecular Basis of Melanoma, MDACC Grand Rounds-Genetic Portraits of Advanced Cancers at MD Anderson, MD Anderson Cancer Center, Houston, TX, 9/25/2015

**Davies MA.** Immunotherapy Clinical Studies Across Tumor Types: Malignant Melanoma, Immune Checkpoint Inhibitors in the Treatment of Selected Tumor Types: A New Direction, CancerNet and A. Webb Roberts Center for CME of Baylor Health Care, Houston, TX, 4/23/2016

**Davies MA,** Lazar A. Melanoma: New Insights into Oncogenes, Immunology, Metastasis, and Resistance, 4th Annual Departmental Retreat, Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX, 6/10/2016

**Davies MA.** Target Therapy for BRAF Mutant Melanoma, The Art and Science of Managing the New Melanoma Landscape -A Case Based Multidisciplinary Approach, MD Anderson Melanoma, CME Conference Management, Houston, TX, 9/2016

**Davies MA.** Controversies in Melanoma-BRAF Mutant Disease, MDACC Institution Grand Rounds, MD Anderson, Houston, TX, 10/2016

**Davies, MA.** Melanoma-How Research is Transforming Patient Care and Outcomes, Surviving Cancer, Technical Workshop ITERT, MD Anderson, Houston, TX, 11/2016

**Davies MA.** Systemic Therapy for Melanoma, Current Concepts in Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, 11/2016

**Davies MA.** The Melanoma Moon Shot: New Paradigms, Progress and Opportunities, Advances in Oncology Institutional Grand Rounds, MD Anderson Cancer Center, Houston, TX, 7/14/2017

**Davies MA.** Targeted Therapy of Melanoma, Medical Education Workshop on Melanoma Management, MDACC, Houston, TX, 9/2017

**Davies MA.** Targeted Therapy for BRAF-Mutant Melanoma, 2017, Melanoma Medical Oncology Grand Rounds, MD Anderson Cancer Center, Houston, TX, 11/2017

**Davies MA.** New Approaches to Immunotherapy, Innovative Strategies for Improved Cancer Outcomes, MD Anderson Cancer Center, Houston, TX, 11/2/2018

**Davies MA.** Big Survey, MMO Grand Rounds, MD Anderson Cancer Center, Houston, TX, 6/19/2019

## **PROFESSIONAL MEMBERSHIPS/ACTIVITIES**

### **Professional Society Activities, with Offices Held National and International**

American Medical Association  
Member, 2000-2003

American Society of Clinical Oncology  
Member, 2004-present

American Association for Cancer Research  
Member, 2008-present

Society for Melanoma Research  
Executive Committee Member, 2010-present

MD Anderson Melanoma Moon Shot, Houston, TX  
Co-Leader, 2011-present

American Society for Clinical Investigation  
Member, 2015-present

Clinical Cancer Research  
Editorial Board Member, 2015-present

SWOG  
Melanoma Committee Working Group, 4/2015-present

Society for Melanoma Research  
Executive Secretary, 11/2018-present

**Local/State**

Harris County Medical Association, Houston, TX  
Member, 2007-present

**UNIQUE ACTIVITIES**

1.  
SPORE Webinar, MDACC, "Global Profiling of transcriptional Networks in Melanoma Brain Metastases"

June 11, 2019

2. Sponsored by FDA Brain Metastasis Workshop,  
<https://www.fda.gov/Drugs/NewsEvents/ucm630245.htm>, "CNS Metastases from Melanoma: The Role of Systemic Therapy" <https://vimeo.com/321238550/cb003eb745> Webcast Lecture

February 11, 2019

3. Sponsored by CancerNet, "Update on the Safety and Efficacy of Novel Targeted Therapy Options for Advanced BRAF V600-Mutant Melanoma" and "Update on the Treatment of Malignant Melanoma with Checkpoint Inhibitors and Oncolytic Viral Therapies and Combinations", Recorded Lectures

January 5, 2019

4. Sponsored by CancerNet, "Optimizing Outcomes in Patients with Malignant Melanoma Treated with Targeted Agents, Checkpoint Inhibitors and Oncolytic Viral Therapies", Webcast  
<https://www.mycme.com/optimizing-outcomes-in-patients-with-malignant-melanoma-treated-with-targeted-agents-checkpoint-inhibitors-and-oncolytic-viral-therapies/activity/5766/>

December 28, 2018

5. Sponsored by Melanoma Research Foundation "Melanoma Brain Metastases: Diagnosis and Treatment" Webinar Lecture

October 15, 2018

**DATE OF LAST CV UPDATE**

10/3/2019